<SEC-DOCUMENT>0001628280-25-059077.txt : 20251230
<SEC-HEADER>0001628280-25-059077.hdr.sgml : 20251230
<ACCEPTANCE-DATETIME>20251230080511
ACCESSION NUMBER:		0001628280-25-059077
CONFORMED SUBMISSION TYPE:	S-3
PUBLIC DOCUMENT COUNT:		18
FILED AS OF DATE:		20251230
DATE AS OF CHANGE:		20251230

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECISION BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001357874
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-292478
		FILM NUMBER:		251611083

	BUSINESS ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
		BUSINESS PHONE:		919-314-5512

	MAIL ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-3
<SEQUENCE>1
<FILENAME>precisionbiosiences-sx3.htm
<DESCRIPTION>S-3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_42"></div><div style="min-height:18pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">As filed with the Securities and Exchange Commission on December 30, 2025</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Registration No. 333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Form S-3</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">REGISTRATION STATEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">UNDER</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-style:italic;font-weight:700;line-height:120%">THE SECURITIES ACT OF 1933</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Precision BioSciences, Inc.</font></div><div style="margin-bottom:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Delaware</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">20-4206017</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Identification Number)</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">302 East Pettigrew St., Suite A-100</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Durham, North Carolina 27701</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(919) 314-5512</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Michael Amoroso</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Precision BioSciences, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">302 East Pettigrew St., Suite A-100</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Durham, North Carolina 27701</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(919) 314-5512</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of agent for service)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Copies to&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Peter N. Handrinos, Esq.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Nathan Ajiashvili, Esq.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Latham &#38; Watkins LLP</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">200 Clarendon Street</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">Boston, Massachusetts 02116</font></div><div style="margin-bottom:4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">(617) 948-6000</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:16.792%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> From time to time after the effective date of this registration statement.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.  </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%"> </font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective on filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.622%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-accelerated filer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Smaller reporting company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Emerging growth company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. </font><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:120%">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.</font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_45"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This registration statement contains&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a base prospectus which covers the offering, issuance and sale by us of up to $250,000,000 in the aggregate of the securities identified above from time to time in one or more offerings&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a sales agreement prospectus supplement covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $60,000,000 of our common stock that may be issued and sold under a sales agreement with Jefferies LLC.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The base prospectus immediately follows this explanatory note. The specific terms of any securities to be offered pursuant to the base prospectus will be specified in a prospectus supplement to the base prospectus. The sales agreement prospectus supplement immediately follows the base prospectus. The $60,000,000 of common stock that may be offered, issued and sold under the sales agreement prospectus supplement is included in the $250,000,000 of securities that may be offered, issued and sold by us under the base prospectus. Upon termination of the sales agreement with Jefferies LLC, any portion of the $60,000,000 included in the sales agreement prospectus supplement that is not sold pursuant to the sales agreement will be available for sale in other offerings pursuant to the base prospectus and a corresponding prospectus supplement, and if no shares are sold under the sales agreement, the full $250,000,000 of securities may be sold in other offerings pursuant to the base prospectus and a corresponding prospectus supplement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_48"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#de1a1e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font></div><div style="text-align:center"><font style="color:#de1a1e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Subject to Completion, dated December 30, 2025.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div style="margin-bottom:9pt;text-align:center"><img alt="precisionlogoa.jpg" src="precisionlogoa.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:304px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">$250,000,000</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Common Stock </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Preferred Stock </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Debt Securities </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Warrants</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Units</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may offer and sell up to $250,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering and the amounts, prices and terms of the securities. The prospectus supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement before you invest in any of our securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &#8220;About this Prospectus&#8221; and &#8220;Plan of Distribution&#8221; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#8220;</font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_468" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RISK FACTORS</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8221; ON PAGE </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_468" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">5</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> OF THIS PROSPECTUS AND ANY SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT AND IN THE DOCUMENTS INCLUDED BY REFERENCE IN THIS PROSPECTUS OR ANY PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DTIL.&#8221; On December 26, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $4.23 per share.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The date of this prospectus is              , 2026.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_403"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Page</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_51" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ABOUT THIS PROSPECTUS</a></font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_51" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_425" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">WHERE YOU CAN FIND MORE INFORMATION&#59; INCORPORATION BY REFERENCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_425" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_446" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">THE COMPANY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_446" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_468" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_468" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_489" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_489" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_510" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF CAPITAL STOCK</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_510" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_531" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF DEBT SECURITIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_531" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_558" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF WARRANTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_558" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">19</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_571" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DESCRIPTION OF UNITS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_571" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">21</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_584" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">GLOBAL SECURITIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_584" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">22</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_597" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_597" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">26</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_610" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_610" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_623" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EXPERTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_623" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">28</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_51"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $250,000,000 as described in this prospectus. Each time that we offer and sell securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect to that offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable. Before purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the heading &#8220;Where You Can Find More Information&#59; Incorporation by Reference.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplement or any applicable free writing prospectus may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; contained in this prospectus, the applicable prospectus supplement and any applicable free writing prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When we refer to &#8220;Precision,&#8221; &#8220;we,&#8221; &#8220;our company,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; in this prospectus, we mean Precision BioSciences, Inc. and its consolidated subsidiaries, unless otherwise specified. When we refer to &#8220;you,&#8221; we mean the potential holders of the applicable series of securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_425"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION&#59; INCORPORATION BY REFERENCE </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http&#58;&#47;&#47;www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our website address </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.precisionbiosciences.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The information on our website, however, is not, and should not be deemed to be, a part of this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC&#8217;s website, as provided above.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Incorporation by Reference</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the SEC (other than those documents or the portions of those documents not deemed to be filed)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Annual Report on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017025044775/dtil-20241231.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2024, filed with the SEC on March 26, 2025 and the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2024 from our Definitive Proxy Statement on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000114036125013867/ny20038513x772_def14a.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 14A</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on April 15, 2025.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Quarterly Reports on Form 10-Q for the quarters ended </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025071991/dtil-20250331.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 31, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on May 15, 2025, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025038594/dtil-20250630.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">June 30, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on August 7, 2025, and </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025047919/dtil-20250930.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">September 30, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on November 3, 2025.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Current Reports on Form 8-K, filed with the SEC on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017025003290/dtil-20250106.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">January 8, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Item 8.01 only), </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025010209/dtil-20250123.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">January 29, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025035562/dtil-20250304.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 7, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025038094/dtil-20250806.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">August 6, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Item 8.01 only), </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000135787425000005/dtil-20250826.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">September 2, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1357874/000162828025051382/dtil-20251110.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">November 10, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Item 8.01 only), and </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025051382/dtil-20251110.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">November 12, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The description of our Common Stock contained in our Registration Statement on Form 8-A, filed with the SEC on March 19, 2019, as updated by &#8220;Description of Registrant&#8217;s Securities Registered pursuant to Section 12 of the Exchange Act of 1934, as amended&#8221; filed as Exhibit 4.4 to our Annual Report on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020002196/btai-20191231x10k.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form</a><a href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020002196/btai-20191231x10k.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;</a><a href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020002196/btai-20191231x10k.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">10-K</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal year ended December 31, 2024, and any amendment or report filed for the purpose of updating such description.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &#8220;Exchange Act&#8221; in this prospectus, prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration statement, but excluding any information </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">You may request a free copy of any of the documents incorporated by reference in this prospectus by writing or telephoning us at the following address&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Precision BioSciences, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">302 East Pettigrew St., Suite A-100</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Durham, North Carolina</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(919) 314-5512</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any accompanying prospectus supplement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_446"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">THE COMPANY</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage gene editing company dedicated to improving life by developing </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> therapies for genetic and infectious diseases with the application of our wholly-owned proprietary ARCUS genome editing platform. The foundation of ARCUS is a natural homing endonuclease which allows us to replicate precise gene editing as it evolved in nature for sophisticated gene edits, including gene insertion, excision, and elimination. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our proprietary ARCUS genome editing platform to advance </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing programs that go beyond gene knockouts in the liver and carry out more sophisticated edits such as gene insertions, gene excision, and gene elimination, unlocking a broader potential for ARCUS in vivo gene editing in human therapeutics.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PBGENE-HBV is our wholly owned </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic Hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate cccDNA and inactivate integrated HBV DNA, the root cause chronic Hepatitis B. The ELIMINATE-B trial is investigating PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level in patients with chronic Hepatitis B. The ELIMINATE-B trial is recruiting patients in the United States, Hong Kong, New Zealand and the United Kingdom. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Duchenne muscular dystrophy (&#8220;DMD&#8221;) is a genetic disease caused by mutations in the dystrophin gene that prevent production of the dystrophin protein and affects approximately 15,000 patients in the United States alone. There are currently no approved therapies with curative intent that can drive durable and significant functional improvements over time. PBGENE-DMD is designed to improve function for more than 60% of patients afflicted with DMD by employing two complementary ARCUS nucleases delivered in a single AAV to excise exons 45-55 of the dystrophin gene. The aim of this approach is to restore a near-full length functional dystrophin protein within the body that more closely resembles normal dystrophin as opposed to synthetic, truncated dystrophin approaches with minimal functional benefit. We have completed final toxicology studies and are manufacturing clinical supplies with an anticipated U.S. investigational new drug (&#8220;IND&#8221;) filing by the end of 2025.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in January 2006. Our principal executive offices are located at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, and our telephone number is (919) 314-5512. Our website address is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.precisionbiosciences.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our securities. Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DTIL.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_468"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves significant risks. You should carefully consider the risk factors incorporated by reference to our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or Current Reports on Form 8-K we file after the date of this prospectus, and all other information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any applicable free writing prospectus before making a decision about investing in our securities. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Some of the principal risks and uncertainties include, but are not limited to, the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since our inception and expect to continue to incur losses for the foreseeable future. We have not been profitable and may not achieve or maintain profitability.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding, and if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate development. We have not yet been able to assess the safety and efficacy of most of our product candidates in humans.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily dependent on the successful development and translation of ARCUS, and due to the early stages of our product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition in industries experiencing rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop product candidates or treatments that are safer or more effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any of our product candidates.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future profitability, if any, will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory landscape that will apply to development of therapeutic product candidates by us or our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any product candidates that we or our collaborators or other licensees may develop will be novel and may be complex and difficult to manufacture, and if we experience manufacturing problems, it could result in delays in development and commercialization of such product candidates or otherwise harm our business.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approval for any products that we develop alone or with collaborators, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if any product we develop alone or with collaborators receives marketing approval, such product may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our key executives, as well as attracting, retaining and motivating qualified personnel.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we no longer qualify as an emerging growth company, we are subject to additional laws and regulations affecting public companies that may increase our costs and the demands on our management which could harm our operating results. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_489"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_510"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our capital stock is not complete and may not contain all the information you should consider before investing in our capital stock. This description is summarized from, and qualified in its entirety by reference to, our amended and restated certificate of incorporation and our amended and restated bylaws, each of which has been publicly filed with the SEC. See &#8220;Where You Can Find More Information&#59; Incorporation by Reference.&#8221;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Authorized Capital Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 200,000,000 shares of common stock, par value $0.000005 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which are undesignated.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DTIL.&#8221;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting Rights.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the votes cast. All other elections and questions presented to the stockholders shall be decided by the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively (excluding abstentions) at the meeting by the holders entitled to vote thereon. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights Upon Liquidation.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive proportionately our net assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Rights.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Holders of our common stock have no preemptive, subscription, redemption or conversion rights. Our outstanding shares of common stock are, and the shares offered by us under this prospectus will be, when issued and paid for, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Dividend</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors our board of directors deems relevant, and subject to any restrictions applicable to us contained in any future financing instruments.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third-party to acquire, or could discourage a third-party from seeking to acquire, a majority of our outstanding voting stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Anti-takeover Provisions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Some provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult&#58; an acquisition of us by means of a tender offer&#59; an acquisition of us by means of a proxy contest or otherwise&#59; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interests or in our best interests, including transactions that provide for payment of a premium over the market price for our shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undesignated Preferred Stock</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The ability of our board of directors, without action by our stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to effect a change in control of the Company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of the Company.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder Meetings</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by the chairman of our board of directors, our chief executive officer or president (in the absence of a chief executive officer), or by a resolution adopted by a majority of our board of directors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of our board of directors or a committee of our board of directors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elimination of Stockholder Action by Written Consent</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation eliminates the right of stockholders to act by written consent without a meeting.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Staggered Board</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes. The directors in each class serve for a three-year term, with one class being elected each year by our stockholders. Our amended and restated certificate of incorporation and amended and restated bylaws provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one-third of the directors. This system of electing and removing directors may delay or prevent a change of our management or a change in control of our company and may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Removal of Directors</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote in the election of directors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders Not Entitled to Cumulative Voting</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors will be able to elect all of the directors standing for election, if they choose, other than any directors that holders of our convertible preferred stock may be entitled to elect.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Choice of Forum</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, (3) any action asserting a claim against us arising pursuant to any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws or (4) any action asserting a claim governed by the internal affairs doctrine. Under our amended and restated certificate of incorporation, this exclusive forum provision does not apply to claims which are vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery of the State of Delaware, or for which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. For instance, the provision would not apply to actions brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder. Our amended and restated certificate of incorporation also provides that any person or entity holding, purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our amended and restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that, unless the Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, and that any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to such provision.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment of Charter Provisions</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock and the provision prohibiting cumulative voting, would require approval by holders of at least two-thirds in voting power of the outstanding shares of stock entitled to vote thereon.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Section 203 of the Delaware General Corporation Law</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by our board of directors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_531"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF DEBT SECURITIES</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one or more series.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The debt securities will be issued under an indenture between us and a trustee to be named in the applicable indenture. We have summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As used in this section only, &#8220;Precision,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; refer to Precision BioSciences, Inc., excluding our subsidiaries, unless expressly stated or the context otherwise requires.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the manner provided in a resolution of our board of directors, in an officer&#8217;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating to such series (including any pricing supplement or term sheet).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We can issue an unlimited amount of debt securities under the indenture that may be in one or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being offered, the aggregate principal amount and the following terms of the debt securities, if applicable&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the title and ranking of the debt securities (including the terms of any subordination provisions)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any limit on the aggregate principal amount of the debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date or dates on which the principal of the securities of the series is payable&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates (including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable and any regular record date for the interest payable on any interest payment date&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may redeem the debt securities&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the holders of debt securities and other detailed terms and provisions of these repurchase obligations&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal amount&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the currency of denomination of the debt securities, which may be U.S. Dollars or any foreign currency, and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and interest on the debt securities will be made&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any provisions relating to any security provided for the debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with respect to the debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to the debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including, if applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including the terms of subordination, if any, of such guarantees. (Section 2.2)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">you with information on the federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus supplement.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Transfer and Exchange</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each debt security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security as a &#8220;book-entry debt security&#8221;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#8220;certificated debt security&#8221;) as set forth in the applicable prospectus supplement. Except as set forth under the heading &#8220;Global Debt Securities and Book-Entry System&#8221; below, book-entry debt securities will not be issuable in certificated form.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Certificated Debt Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection with a transfer or exchange. (Section 2.7)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of a new certificate to the new holder.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Debt Securities and Book-Entry System</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#8220;Global Securities.&#8221;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Covenants</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities. (Article IV)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">No Protection in the Event of a Change of Control</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation, Merger and Sale of Assets</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person (a &#8220;successor person&#8221;) unless&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we are the surviving corporation or the successor person (if other than Precision) is a corporation organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its properties to us. (Section 5.1)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Events of Default</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Event of Default&#8221; means with respect to any series of debt securities, any of the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the 30-day period)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">default in the payment of principal of any security of that series at its maturity&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or we and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Precision&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other Event of Default provided with respect to debt securities of that series that is described in the applicable prospectus supplement. (Section 6.1)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No Event of Default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will provide the trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action we are taking or propose to take in respect thereof. (Section 6.1)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an Event of Default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind and annul the acceleration if all Events of Default, other than the non-payment of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the indenture. (Section 6.2) We refer you to the prospectus supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount securities upon the occurrence of an Event of Default.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The indenture provides that the trustee may refuse to perform any duty or exercise any of its rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">to the trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">No holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to debt securities of that series&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section 6.8)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture. (Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each Securityholder of the securities of that series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice is in the interest of the holders of those debt securities. (Section 7.5)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Modification and Waiver</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to cure any ambiguity, defect or inconsistency&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to comply with covenants in the indenture described above under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221;&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to provide for uncertificated securities in addition to or in place of certificated securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to surrender any of our rights or powers under the indenture&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to add covenants or events of default for the benefit of the holders of debt securities of any series&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to comply with the applicable procedures of the applicable depositary&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to make any change that does not adversely affect the rights of any holder of debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series as permitted by the indenture&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act. (Section 9.1)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may also modify and amend the indenture with the consent of the holders of at least a majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then outstanding if that amendment will&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce the principal amount of discount securities payable upon acceleration of maturity&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such acceleration)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make the principal of, premium or interest on any debt security payable in currency other than that stated in the debt security&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">waive a redemption payment with respect to any debt security. (Section 9.3)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration. (Section 6.13)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Defeasance of Debt Securities and Certain Covenants in Certain Circumstances</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Defeasance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and&#47;or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has been published by, the U.S. Internal Revenue Service a ruling or, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">since the date of execution of the indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3)</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defeasance of Certain Covenants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon compliance with certain conditions&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may omit to comply with the covenant described under the heading &#8220;Consolidation, Merger and Sale of Assets&#8221; and certain other covenants set forth in the indenture, as well as any additional covenants that may be set forth in the applicable prospectus supplement&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to the debt securities of that series (&#8220;covenant defeasance&#8221;).</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The conditions include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">depositing with the trustee money and&#47;or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4)</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">No Personal Liability of Directors, Officers, Employees or Securityholders</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None of our past, present or future directors, officers, employees or securityholders, as such, will have any liability for any of our obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">However, this waiver and release may not be effective to waive liabilities under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Governing Law</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by the laws of the State of New York.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated thereby.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we, the trustee and the holder of the debt securities (by their acceptance of the debt securities) irrevocably submit to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth in the indenture will be effective service of process for any suit, action or other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section 10.10)</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_558"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF WARRANTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant agreements and warrant certificates that contain the terms of the warrants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The particular terms of any issue of warrants will be described in the prospectus supplement relating to the issue. Those terms may include&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase such shares and the price at which such number of shares may be purchased upon such exercise&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants, which may be payable in cash, securities or other property&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common stock will be separately transferable&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms of any rights to redeem or call the warrants&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. Federal income tax consequences applicable to the warrants&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any additional terms of the warrants, including terms, procedures and limitations relating to the exchange, exercise and settlement of the warrants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Holders of equity warrants will not be entitled&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to vote, consent or receive dividends&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exercise any rights as stockholders of Precision.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will not have any rights of holders of the debt securities that can be purchased </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">upon exercise, including any rights to receive payments of principal of, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution or winding up on the common stock or preferred stock, if any.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_571"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF UNITS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the unit agent in the applicable prospectus supplement relating to a particular series of units.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following description, together with the additional information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions, and we will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the following, as applicable&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the title of the series of units&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification and description of the separate constituent securities comprising the units&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price or prices at which the units will be issued&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date, if any, on and after which the constituent securities comprising the units will be separately transferable&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a discussion of certain U.S. federal income tax considerations applicable to the units&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any other terms of the units and their constituent securities.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_584"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GLOBAL SECURITIES</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Book-Entry, Delivery and Form</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless we indicate differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global securities. The global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or DTC, and registered in the name of Cede &#38; Co., the nominee of DTC. Unless and until it is exchanged for individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or its nominee to a successor depositary or to a nominee of the successor depositary.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">DTC has advised us that it is&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited-purpose trust company organized under the New York Banking Law&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a &#8220;banking organization&#8221; within the meaning of the New York Banking Law&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a member of the Federal Reserve System&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform Commercial Code&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a &#8220;clearing agency&#8221; registered pursuant to the provisions of Section 17A of the Exchange Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#8217; accounts, thereby eliminating the need for physical movement of securities certificates. &#8220;Direct participants&#8221; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust &#38; Clearing Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules applicable to DTC and its participants are on file with the SEC.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of securities under the DTC system must be made by or through direct participants, which will receive a credit for the securities on DTC&#8217;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect participants&#8217; records. Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions, as well as periodic statements of their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of DTC&#8217;s partnership nominee, Cede &#38; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede &#38; Co. or such other nominee will not change the beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#8217;s records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">So long as the securities are in book-entry form, you will receive payments and may transfer securities only through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">respect of the securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#8217;s practice is to determine by lot the amount of the interest of each direct participant in the securities of such series to be redeemed.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Neither DTC nor Cede &#38; Co. (or such other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting rights of Cede &#38; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered owner of such securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable securities herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede &#38; Co., or such other nominee as may be requested by an authorized representative of DTC. DTC&#8217;s practice is to credit direct participants&#8217; accounts upon DTC&#8217;s receipt of funds and corresponding detail information from us on the payment date in accordance with their respective holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered in &#8220;street name.&#8221; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend payments to Cede &#38; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility&#59; disbursement of payments to direct participants is the responsibility of DTC, and disbursement of payments to the beneficial owners is the responsibility of direct and indirect participants.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Except under the limited circumstances described below, purchasers of securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise any rights under the securities and the indenture.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions may require that some purchasers of securities take physical delivery of securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">DTC may discontinue providing its services as securities depositary with respect to the securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be printed and delivered.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, beneficial owners of a particular series of securities generally will not receive certificates representing their ownership interests in those securities. However, if&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">within 90 days of the notification to us or of our becoming aware of DTC&#8217;s ceasing to be so registered, as the case may be&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an Event of Default has occurred and is continuing with respect to such series of securities,</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Euroclear and Clearstream</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If so provided in the applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as &#8220;Clearstream,&#8221; or Euroclear Bank S.A.&#47;N.V., as operator of the Euroclear System, which we refer to as &#8220;Euroclear,&#8221; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations that are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their respective participants through customers&#8217; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#8217; securities accounts in such depositaries&#8217; names on DTC&#8217;s books.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Clearstream and Euroclear are securities clearance systems in Europe. Clearstream and Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating the need for physical movement of certificates.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Payments, deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other participants in DTC, on the other hand, are also subject to DTC&#8217;s rules and procedures.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investors will be able to make and receive through Euroclear and Clearstream payments, deliveries, transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United States.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cross-market transfers between participants in DTC, on the one hand, and participants in Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#8217;s rules on behalf of Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries&#59; however, such cross-market transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system. Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the global securities through DTC, and making or receiving payment in accordance with normal procedures for same-day fund settlement. Participants in Euroclear or Clearstream may not deliver instructions directly to their respective U.S. depositaries.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Due to time zone differences, the securities accounts of a participant in Euroclear or Clearstream purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing day (which must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in Euroclear or Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream following DTC&#8217;s settlement date.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters. In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time. Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants of these or any other rules or procedures governing their respective operations.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">25</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_597"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PLAN OF DISTRIBUTION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods or through underwriters or dealers, through agents and&#47;or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at a fixed price or prices, which may be changed&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at market prices prevailing at the time of sale&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at prices related to such prevailing market prices&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">at negotiated prices.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of resale.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and&#47;or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any common stock will be listed on the Nasdaq Capital Market, but any other securities may or may not be listed on a national securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">27</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_610"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on behalf of Precision BioSciences, Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement.</font></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_623"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Precision BioSciences, Inc. incorporated by reference in this Prospectus have been audited by Deloitte &#38; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm, given upon their authority as experts in accounting and auditing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">28</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_54"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center"><img alt="precisionlogoa.jpg" src="precisionlogoa.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:304px"></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">$250,000,000</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Debt Securities</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Units</font></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">PROSPECTUS</font></div><div style="margin-bottom:30pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">, 2026</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_57"></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUPPLEMENT</font></div><div><font style="color:#de1a1e;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">The information in this prospectus supplement is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:9pt;text-align:center"><img alt="precisionlogoa.jpg" src="precisionlogoa.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:304px"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Up to $60,000,000</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have previously entered into an Open Market Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, or the sales agreement, with Jefferies LLC, or Jefferies, dated June 1, 2020, relating to the sale of shares of our common stock. In accordance with the terms of the sales agreement, under this prospectus supplement, we may offer and sell shares of our common stock, $0.000005 par value per share, having an aggregate offering price of up to $60,000,000 from time to time through Jefferies, acting as our agent.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DTIL.&#8221; On December 26, 2025, the last reported sale price of our common stock on the Nasdaq Capital Market was $4.23 per share.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our common stock, if any, under this prospectus supplement will be made by any method permitted that is deemed an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act. Jefferies is not required to sell any specific amount, but will act as our sales agent using commercially reasonable efforts consistent with its normal trading and sales practices on mutually agreed terms between the sales agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Jefferies will be entitled to compensation at a commission rate of up to 3.0% of the gross sales price of the shares of our common stock sold through it pursuant to the sales agreement. In connection with the sale of the common stock on our behalf, Jefferies will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Jefferies with respect to certain liabilities, including liabilities under the Securities Act. See &#8220;Plan of Distribution&#8221; beginning on page S-16 for additional information regarding the compensation to be paid to Jefferies.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#8220;</font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_69" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">RISK FACTORS</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8221; ON PAGE </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_69" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">S-8</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> OF THIS PROSPECTUS SUPPLEMENT AND IN THE DOCUMENTS INCORPORATED BY REFERENCE IN THIS PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">Jefferies</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The date of this prospectus is              , 2026.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_60"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_63" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">ABOUT THIS PROSPECTUS SUPPLEMENT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_63" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_636" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">WHERE YOU CAN FIND MORE INFORMATION&#59; INCORPORATION BY REFERENCE</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_636" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-3</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_658" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">SALES AGREEMENT PROSPECTUS SUPPLEMENT SUMMARY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_658" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-5</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_686" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">THE OFFERING</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_686" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-6</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_69" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">RISK FACTORS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_69" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-8</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_714" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_714" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-11</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_741" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">USE OF PROCEEDS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_741" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-12</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_754" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DIVIDEND POLICY</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_754" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-13</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_1123" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">DILUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_1123" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-14</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_767" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">PLAN OF DISTRIBUTION</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_767" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-16</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_780" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">LEGAL MATTERS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_780" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-17</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_1148" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">EXPERTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_1148" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">S-17</a></font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-i</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_63"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT THIS PROSPECTUS SUPPLEMENT</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This sales agreement prospectus supplement is part of a registration statement that we have filed with the U.S. Securities and Exchange Commission, or the SEC, utilizing a &#8220;shelf&#8221; registration process. By using a shelf registration statement, we may offer shares of our common stock having an aggregate offering price of up to $60,000,000 from time to time under this prospectus supplement at prices and on terms to be determined by market conditions at the time of offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We provide information to you about this offering of our common stock in two separate documents that are bound together&#58; (1) this sales agreement prospectus supplement, which describes the specific details regarding this offering&#59; and (2) the accompanying base prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus supplement,&#8221; we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying base prospectus, you should rely on this prospectus supplement. To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information contained in any document incorporated by reference in this prospectus supplement, on the other hand, you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by reference in this prospectus supplement&#8212;the statement in the document having the later date modifies or supersedes the earlier statement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have not, and Jefferies has not, authorized anyone to provide you with information other than that contained in this prospectus supplement, the accompanying base prospectus and any free writing prospectus. We are not, and Jefferies is not, making an offer to sell or soliciting any offer to buy these securities in any jurisdiction where the offer or sale is not permitted or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying base prospectus, the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying base prospectus, the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering in their entirety before making an investment decision.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Before buying any of the common stock that we are offering, we urge you to carefully read this prospectus supplement, the accompanying base prospectus and all of the information incorporated by reference herein and therein, as well as the additional information described under the heading &#8220;Where You Can Find More Information&#59; Incorporation by Reference.&#8221; These documents contain important information that you should consider when making your investment decision.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">When we refer to &#8220;Precision,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; in this prospectus supplement, we mean Precision BioSciences, Inc. or its consolidated subsidiaries, unless otherwise specified. When we refer to &#8220;you,&#8221; we mean the holders of the applicable series of securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have proprietary rights to trademarks, trade names and service marks appearing in this prospectus that are important to our business. This prospectus supplement also includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus supplement appear without the &#174; and TM symbols, but those references are not intended to indicate, in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-2</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_636"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WHERE YOU CAN FIND MORE INFORMATION&#59; INCORPORATION BY REFERENCE</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.precisionbiosciences.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The information on our website, however, is not, and should not be deemed to be, a part of this prospectus supplement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement and the accompanying base prospectus are part of a registration statement that we filed with the SEC and do not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement. Statements in this prospectus supplement or the accompanying base prospectus about these documents are summaries, and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC&#8217;s website, as provided above.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Incorporation by Reference</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The SEC&#8217;s rules allow us to &#8220;incorporate by reference&#8221; information in this prospectus supplement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or a subsequently filed document incorporated by reference modifies or replaces that statement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement incorporates by reference the documents set forth below that have previously been filed with the SEC (other than those documents or the portions of those documents not deemed to be filed)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Annual Report on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025044775/dtil-20241231.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December 31, 2024, filed with the SEC on March 26, 2025 and the information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2024 from our Definitive Proxy Statement on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000114036125013867/ny20038513x772_def14a.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Schedule 14A</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on April 15, 2025.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Quarterly Reports on Form 10-Q for the quarters ended </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025071991/dtil-20250331.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 31, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on May 15, 2025, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025038594/dtil-20250630.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">June 30, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on August 7, 2025, and </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025047919/dtil-20250930.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">September 30, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on November 3, 2025.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Current Reports on Form 8-K, filed with the SEC on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025003290/dtil-20250106.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">January 8, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Item 8.01 only), </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025010209/dtil-20250123.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">January 29, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000095017025035562/dtil-20250304.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">March 7, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025038094/dtil-20250806.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">August 6, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Item 8.01 only), </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000135787425000005/dtil-20250826.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">September 2, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1357874/000162828025051382/dtil-20251110.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">November 10, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Item 8.01 only) and </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001357874/000162828025051382/dtil-20251110.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">November 12, 2025</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The description of our Common Stock contained in our Registration Statement on Form 8-A, filed with the SEC on March 19, 2019, as updated by &#8220;Description of Registrant&#8217;s Securities Registered pursuant to Section 12 of the Exchange Act of 1934, as amended&#8221; filed as Exhibit 4.4 to our Annual Report on </font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1720893/000155837020002196/btai-20191231x10k.htm" style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Form 10-K</a></font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> for the fiscal year ended December 31, 2024, and any amendment or report filed for the purpose of updating such description.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All reports and other documents we subsequently file pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, which we refer to as the &#8220;Exchange Act&#8221; in this prospectus supplement, prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement of which this prospectus supplement is a part and prior to the effectiveness of the registration statement, will also be incorporated by reference in this prospectus supplement and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">deemed to be part of this prospectus supplement from the date of the filing of such reports and documents. We are not, however, incorporating by reference any documents or portions thereof, whether specifically listed above or filed in the future, that are not deemed &#8220;filed&#8221; with the SEC, including our stock performance graph or any information furnished pursuant to Items 2.02 or 7.01 of Form 8-K or related exhibits furnished pursuant to Item 9.01 of Form 8-K.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">You may request a free copy of any of the documents incorporated by reference in this prospectus supplement by writing or telephoning us at the following address&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Precision BioSciences, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">302 East Pettigrew St., Suite A-100</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Durham, North Carolina</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(919) 314-5512</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus supplement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-4</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_658"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 18.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PROSPECTUS SUPPLEMENT SUMMARY</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This summary provides a general overview of selected information and does not contain all of the information you should consider before buying our common stock. Therefore, you should read this entire prospectus supplement, the accompanying base prospectus and any free writing prospectus that we have authorized for use in connection with this offering carefully, including the information incorporated by reference, before deciding to invest in our common stock. Investors should carefully consider the information set forth under &#8220;Risk Factors&#8221; beginning on page S-8 of this prospectus supplement and incorporated by reference to our annual report on Form 10-K and our quarterly reports on Form 10-Q.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Precision BioSciences, Inc.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage gene editing company dedicated to improving life by developing </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> therapies for genetic and infectious diseases with the application of our wholly-owned proprietary ARCUS genome editing platform. The foundation of ARCUS is a natural homing endonuclease which allows us to replicate precise gene editing as it evolved in nature for sophisticated gene edits, including gene insertion, excision, and elimination. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We are leveraging our proprietary ARCUS genome editing platform to advance </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing programs that go beyond gene knockouts in the liver and carry out more sophisticated edits such as gene insertions, gene excision, and gene elimination, unlocking a broader potential for ARCUS in vivo gene editing in human therapeutics.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">PBGENE-HBV is our wholly owned </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic Hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate cccDNA and inactivate integrated HBV DNA, the root cause chronic Hepatitis B. The ELIMINATE-B trial is investigating PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level in patients with chronic Hepatitis B. The ELIMINATE-B trial is recruiting patients in the United States, Hong Kong, New Zealand and the United Kingdom. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Duchenne muscular dystrophy (&#8220;DMD&#8221;) is a genetic disease caused by mutations in the dystrophin gene that prevent production of the dystrophin protein and affects approximately 15,000 patients in the United States alone. There are currently no approved therapies with curative intent that can drive durable and significant functional improvements over time. PBGENE-DMD is designed to improve function for more than 60% of patients afflicted with DMD by employing two complementary ARCUS nucleases delivered in a single AAV to excise exons 45-55 of the dystrophin gene. The aim of this approach is to restore a near-full length functional dystrophin protein within the body that more closely resembles normal dystrophin as opposed to synthetic, truncated dystrophin approaches with minimal functional benefit. We have completed final toxicology studies and are manufacturing clinical supplies with an anticipated U.S. investigational new drug (&#8220;IND&#8221;) filing by the end of 2025.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated under the laws of the State of Delaware in January 2006. Our principal executive offices are located at 302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701, and our telephone number is (919) 314-5512. Our website address is </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.precisionbiosciences.com</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this prospectus or in deciding whether to purchase our securities. Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;DTIL.&#8221;</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-5</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_686"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 18.00pt 36.00pt"><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">THE OFFERING</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Common stock offered by us</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock having an aggregate offering price of up to $60,000,000.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Common stock to be outstanding after this offering</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">37,082,062&#160;shares of our common stock, assuming sales of 14,184,397 shares of our common stock in this offering at an offering price of $4.23 per share, the last reported sale price of our ordinary shares on the Nasdaq Capital Market on December 26, 2025. The actual number of shares issued will vary depending on the sales price under this offering.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Plan of Distribution</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;At the market offering&#8221; that may be made from time to time on the Nasdaq Capital Market or other existing trading market for our common stock through our agent, Jefferies. See the section entitled &#8220;Plan of Distribution&#8221; on page S-16 of this prospectus supplement.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Use of Proceeds</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the net proceeds of this offering to fund ongoing and planned research and development, and for working capital and other general corporate purposes. See the section entitled &#8220;Use of Proceeds&#8221; on page S-12 of this prospectus supplement.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Risk Factors&#8221; beginning on page S-8 of this prospectus supplement and the other information included in, or incorporated by reference into, this prospectus supplement for a discussion of certain factors you should carefully consider before deciding to invest in shares of our common stock.</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Nasdaq Capital Market symbol</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">DTIL</font></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The number of our shares of our common stock to be outstanding after this offering is based on 22,897,665 shares of our common stock outstanding as of September 30, 2025, after giving effect to the issuance and sale of 10,815,000 shares of our common stock in a registered direct offering (the &#8220;Registered Direct Offering&#8221;) subsequent to September 30, 2025 and further excludes&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">10,007,500 shares of common stock issuable upon exercise of warrants and pre-funded warrants to purchase shares of our common stock outstanding as of September 30, 2025 and after giving effect to the Registered Direct Offering&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">26,029 shares of common stock issuable upon exercise of stock options outstanding at a weighted average exercise price of $304.59 per share under our 2015 Stock Incentive Plan (&#8220;2015 Plan&#8221;) as of September 30, 2025&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">44,493 shares of our common stock issuable upon exercise of stock options outstanding at a weighted average exercise price of $198.60 per share, and 1,623,725 shares of our common stock issuable upon vesting of restricted stock units (&#8220;RSUs&#8221;) outstanding at a weighted grant date fair value price of $7.77 per share under our 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;), as of September 30, 2025&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">98,855 shares of our common stock issuable upon exercise of stock options outstanding at a weighted average exercise price of $114.69 per share and 10,720 shares of our common stock issuable upon vesting of RSUs outstanding at a weighted grant date fair value price of $6.70 per share under our 2021 Employment Inducement Incentive Award Plan (&#8220;Inducement Award Plan&#8221;), as of September 30, 2025&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">79,756 shares of our common stock reserved for future issuance under our 2019 Employee Stock Purchase Plan (&#8220;2019 ESPP&#8221;), as of September 30, 2025&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">381,225 shares of our common stock reserved for future issuance under our Inducement Award Plan, as of September 30, 2025&#59; and</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="border-color:#000000;border-style:solid;border-width:1.00pt;padding:36.00pt 36.00pt 18.00pt 36.00pt"><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,126,522 shares of our common stock sold pursuant to the Open Market Sale Agreement, dated June 1, 2020, with Jefferies LLC (the &#8220;Existing Sales Agreement&#8221;) in &#8220;at the market&#8221; offerings subsequent to September 30, 2025.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding options or settlement of the outstanding RSUs referred to above after September 30, 2025.</font></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-7</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_69"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investment in any securities offered pursuant to this prospectus supplement and the accompanying base prospectus involves risks. You should carefully consider the risk factors described below and in our most recent Annual Report on Form 10-K and any amendment or update thereto reflected in subsequent filings with the SEC, including in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, and all other information contained or incorporated by reference in this prospectus supplement, as updated by our subsequent filings under the Exchange Act. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Some of the principal risks and uncertainties include, but are not limited to, the following&#58; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since our inception and expect to continue to incur losses for the foreseeable future. We have not been profitable and may not achieve or maintain profitability.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding, and if we are unable to raise a sufficient amount of capital when needed on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARCUS is a novel technology, making it difficult to predict the time, cost and potential success of product candidate development. We have not yet been able to assess the safety and efficacy of most of our product candidates in humans.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are heavily dependent on the successful development and translation of ARCUS, and due to the early stages of our product development operations, we cannot give any assurance that any product candidates will be successfully developed and commercialized.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adverse public perception of genome editing may negatively impact the developmental progress or commercial success of products that we develop alone or with collaborators.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face significant competition in industries experiencing rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop product candidates or treatments that are safer or more effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any of our product candidates.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future profitability, if any, will depend in part on our ability and the ability of our collaborators to commercialize any products that we or our collaborators may develop in markets throughout the world. Commercialization of products in various markets could subject us to risks and uncertainties.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any products that we develop alone or with collaborators.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory landscape that will apply to development of therapeutic product candidates by us or our collaborators is rigorous, complex, uncertain and subject to change, which could result in delays or termination of development of such product candidates or unexpected costs in obtaining regulatory approvals.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully and timely conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any product candidates that we or our collaborators or other licensees may develop will be novel and may be complex and difficult to manufacture, and if we experience manufacturing problems, it could result in delays in development and commercialization of such product candidates or otherwise harm our business.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approval for any products that we develop alone or with collaborators, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if any product we develop alone or with collaborators receives marketing approval, such product may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our key executives, as well as attracting, retaining and motivating qualified personnel.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we no longer qualify as an emerging growth company, we are subject to additional laws and regulations affecting public companies that may increase our costs and the demands on our management which could harm our operating results. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. You should read this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to this Offering</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If you purchase shares of our common stock sold in this offering, you will experience immediate and substantial dilution in the net tangible book value of your shares. In addition, we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to you.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The price per share of our common stock being offered may be higher than the net tangible book value per share of our outstanding common stock prior to this offering. Assuming that an aggregate of 14,184,397 shares of our common stock are sold at a price of $4.23 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on December 26, 2025, for aggregate gross proceeds of approximately $60.0 million, and after deducting commissions and estimated offering expenses payable by us, new investors in this offering will incur immediate dilution of $0.35 per share. For a more detailed discussion of the foregoing, see the section entitled &#8220;Dilution&#8221; below. To the extent outstanding stock options are exercised, there will be further dilution to new investors. In addition, to the extent we need to raise additional capital in the future and we issue additional shares of common stock or securities convertible or exchangeable for our common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered in this offering.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of the net proceeds from this offering and may not use them effectively.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our management will have broad discretion in the application of the net proceeds from this offering, including for any of the purposes described in the section entitled &#8220;Use of Proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment. We expect to use the net proceeds from this offering to fund ongoing and planned research and development, and for working capital and other general corporate purposes. The failure by our management to apply these funds effectively could harm our business. Pending their use, we plan to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales or issuances of our common stock in the public markets, or the perception of such sales, could depress the trading price of our common stock.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The sale of a substantial number of shares of our common stock or other equity-related securities in the public markets, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We may sell large quantities of our common stock at any time pursuant to this prospectus supplement or in one or more separate offerings. We cannot predict the effect that future sales of common stock or other equity-related securities would have on the market price of our common stock.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The actual number of shares we will issue under the sales agreement, at any one time or in total, is uncertain.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to deliver a placement notice to Jefferies at any time throughout the term of the sales agreement. The number of shares that are sold by Jefferies after delivering a placement notice will fluctuate based on the market price of our common stock during the sales period and limits we set with Jefferies. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares that will be ultimately issued.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The common stock offered hereby will be sold in &#8220;at the market offerings,&#8221; and investors who buy shares at different times will likely pay different prices.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Investors who purchase shares in this offering at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-10</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_714"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus that we have authorized for use in connection with this offering may contain forward-looking statements. All statements other than statements of present and historical facts contained in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus, including, without limitation, statements regarding our future results of operations and financial position, business strategy and approach including the further development and potential of our PBGENE-HBV program and ELIMINATE-B clinical trial and the expected timing of clinical milestones, related results, prospective products, use and development of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> gene editing products incorporating our custom ARCUS nucleases for the purpose of seeking to research and develop potential treatments for certain diseases, planned preclinical studies and clinical trials, or discontinuance thereof, the status and results of our preclinical studies, expected release of interim data, expectations regarding the use and effects of ARCUS, including in connection with </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, collaborations and potential new partnerships or alternative opportunities for our product candidates, potential new application filings and regulatory approvals, research and development costs, timing, expected results and likelihood of success, plans and objectives of management for future operations, as well as the impact of local and global health epidemics or geopolitical conflicts may be forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. This prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus may also contain estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;seek&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the respective dates of this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus, as applicable, and are subject to a number of risks, uncertainties and assumptions, including those described under &#8220;Risk Factors&#8221; and elsewhere in this prospectus supplement. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein and any free writing prospectus, whether as a result of any new information, future events, changed circumstances or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-11</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_741"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">USE OF PROCEEDS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $60.0 million from time to time. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the net proceeds of this offering to fund ongoing and planned research and development, and for working capital and other general corporate purposes. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of our clinical trials and other development efforts and other factors described under &#8220;Risk Factors&#8221; in this prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein and therein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the use of the net proceeds described above, we plan to invest the net proceeds from this offering in a variety of capital preservation investments, including short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-12</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_754"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DIVIDEND POLICY</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-13</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_1123"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">DILUTION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If you invest in our common stock, your interest will be diluted to the extent of the difference between the price per share you pay in this offering and the net tangible book value per share of our common stock immediately after this offering. Our net tangible book value of our common stock as of September 30, 2025 was approximately $15.6 million, or approximately $1.29 per share of common stock based upon 12,082,665 shares outstanding. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares outstanding as of September 30, 2025.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our pro forma net tangible book value of our common stock as of September 30, 2025 was approximately $85.6 million, or approximately $3.74 per share of common stock. Pro forma net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares outstanding as of September 30, 2025, after giving effect to the issuance and sale of 10,815,000 shares of our common stock, pre-funded warrants to purchase up to 1,400,000 shares of our common stock and warrants to purchase up to 6,107,500 shares of our common stock for an aggregate purchase price of approximately $75.0 million in the Registered Direct Offering subsequent to September 30, 2025.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">After giving effect to the sale of our common stock in the aggregate amount of $60.0 million at an assumed offering price of $4.23 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on December 26, 2025, and after deducting commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of September 30, 2025 would have been $143.8 million, or $3.88 per share of common stock. This represents an immediate increase in net tangible book value of $0.14 per share to our existing stockholders and an immediate dilution in net tangible book value of $0.35 per share to new investors in this offering.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates this calculation on a per share basis. The pro forma as adjusted information is illustrative only and will adjust based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares of our common stock are sold pursuant to this prospectus supplement. The pro forma as adjusted information assumes that all of our common stock in the aggregate amount of $60.0 million is sold at the assumed offering price of $4.23 per share, the last reported sale price of our common stock on the Nasdaq Capital Market on December 23, 2025. The shares sold in this offering, if any, will be sold from time to time at various prices.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Assumed public offering price per share</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$4.23</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Net tangible book value per share as of September 30, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$1.29</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma increase in net tangible book value per share attributable to the Registered Direct Offering</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2.45</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma net tangible book value per share as of September 30, 2025</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.74</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Increase in pro forma net tangible book value per share attributable to the offering</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">0.14</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Pro forma as adjusted net tangible book value per share after giving effect to the offering</font></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.88</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dilution per share to new investors participating in the offering</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$0.35</font></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The figures in the dilution table above exclude, as of September 30, 2025&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">10,007,500 shares of common stock issuable upon exercise of warrants and pre-funded warrants to purchase shares of our common stock outstanding as of September 30, 2025 and after giving effect to the Registered Direct Offering&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">26,029 shares of common stock issuable upon exercise of stock options outstanding at a weighted average exercise price of $304.59 per share under our 2015 Plan, as of September 30, 2025&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">44,493 shares of our common stock issuable upon exercise of stock options outstanding at a weighted average exercise price of $198.60 per share, and 1,623,725 shares of our common stock issuable upon vesting of RSUs outstanding at a weighted grant date fair value price of $7.77 per share under our 2019 Plan, as of September 30, 2025&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">98,855 shares of our common stock issuable upon exercise of stock options outstanding at a weighted average exercise price of $114.69 per share and 10,720 shares of our common stock issuable upon vesting of RSUs outstanding at a weighted grant date fair value price of $6.70 per share under our Inducement Award Plan, as of September 30, 2025&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">79,756 shares of our common stock reserved for future issuance under our 2019 ESPP, as of September 30, 2025&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">381,225 shares of our common stock reserved for future issuance under our Inducement Award Plan, as of September 30, 2025&#59; and </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">1,126,522 shares of our common stock sold pursuant to the Existing Sales Agreement in &#8220;at the market&#8221; offerings subsequent to September 30, 2025. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, all information contained in this prospectus supplement assumes no exercise of the outstanding options or settlement of the outstanding RSUs referred to above after September 30, 2025.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that outstanding stock options are exercised, outstanding RSUs are vested, new stock options or RSUs are issued, warrants or pre-funded warrants are exercised or we issue additional shares of common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-15</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_767"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PLAN OF DISTRIBUTION</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have previously entered into a sales agreement with Jefferies, under which we may offer and sell our shares of common stock from time to time through Jefferies acting as agent. Pursuant to this prospectus supplement and the accompanying prospectus, we may offer and sell shares of our common stock for up to $60,000,000. Sales of our shares of common stock, if any, under this prospectus supplement and the accompanying prospectus will be made by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Each time we wish to issue and sell shares of common stock under the sales agreement, we will notify Jefferies of the number of shares to be issued, the dates on which such sales are anticipated to be made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have so instructed Jefferies, unless Jefferies declines to accept the terms of such notice, Jefferies has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Jefferies under the sales agreement to sell our shares of common stock are subject to a number of conditions that we must meet. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The settlement of sales of shares between us and Jefferies is generally anticipated to occur on the first trading day following the date on which the sale was made. Sales of our shares of common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Jefferies may agree upon. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We will pay Jefferies a commission of up to 3.0% of the aggregate gross proceeds we receive from each sale of our shares of common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. We estimate that the total expenses for the offering will be approximately $1.9 million. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Jefferies will provide written confirmation to us before the open on The Nasdaq Capital Market on the day following each day on which shares of common stock are sold under the sales agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of the shares of common stock on our behalf, Jefferies will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of Jefferies will be deemed to be underwriting commissions or discounts. We have agreed to indemnify Jefferies against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Jefferies may be required to make in respect of such liabilities. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The offering of our shares of common stock pursuant to the sales agreement will terminate as permitted therein.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed as an exhibit to the registration statement of which this prospectus supplement forms a part. </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Jefferies and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services they may in the future receive customary fees. In the course of its business, Jefferies may actively trade our securities for its own account or for the accounts of customers, and, accordingly, Jefferies may at any time hold long or short positions in such securities.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Jefferies, and Jefferies may distribute the prospectus supplement and the accompanying prospectus electronically.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-16</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_780"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL MATTERS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on behalf of Precision BioSciences, Inc. Jefferies LLC is being represented in connection with this offering by Cooley LLP, New York, New York.</font></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_1148"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">EXPERTS</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Precision BioSciences, Inc. incorporated by reference in this Prospectus have been audited by Deloitte &#38; Touche LLP, an independent registered public accounting firm, as stated in their report. Such financial statements are incorporated by reference in reliance upon the report of such firm, given their authority as experts in accounting and auditing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">S-17</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_72"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:30pt;text-align:center"><img alt="precisionlogoa.jpg" src="precisionlogoa.jpg" style="height:80px;margin-bottom:5pt;vertical-align:text-bottom;width:304px"></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Up to $60,000,000</font></div><div style="margin-bottom:30pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PROSPECTUS SUPPLEMENT</font></div><div style="margin-bottom:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:21.314%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:16pt;font-weight:700;line-height:120%">Jefferies</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">, 2026</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt"><font><br></font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_75"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART II</font></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION NOT REQUIRED IN PROSPECTUS</font></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_794"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Other Expenses of Issuance and Distribution</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby, other than the SEC registration fee.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">SEC registration fee</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">34,525&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Printing expenses</font></div></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Legal fees and expenses</font></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Accounting fees and expenses</font></div></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Blue Sky, qualification fees and expenses</font></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Transfer agent fees and expenses</font></div></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trustee fees and expenses</font></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Warrant agent fees and expenses</font></div></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous</font></div></td><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></div></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be estimated at this time.</font></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_815"></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Indemnification of Directors and Officers</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subsection (a) of Section 145 of the General Corporation Law of the State of Delaware, or the DGCL, empowers a corporation to indemnify any person who was or is a party or who is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the person&#8217;s conduct was unlawful.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Subsection (b) of Section 145 empowers a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that the person acted in any of the capacities set forth above, against expenses (including attorneys&#8217; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Section 145 further provides that to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (a) and (b) of Section 145, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys&#8217; fees) actually and reasonably incurred by such person in connection therewith&#59; that indemnification provided for by Section 145 shall not be deemed exclusive of any other rights to which the indemnified party may be entitled&#59; and the indemnification provided for by Section 145 shall, unless otherwise provided when authorized or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">II-1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ratified, continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit of such person&#8217;s heirs, executors and administrators. Section 145 also empowers the corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of his status as such, whether or not the corporation would have the power to indemnify such person against such liabilities under Section 145.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Section 102(b)(7) of the DGCL provides that a corporation&#8217;s certificate of incorporation may contain a provision eliminating or limiting the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> that such provision shall not eliminate or limit the liability of a director (i) for any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal benefit.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Any underwriting agreement or distribution agreement that the registrant enters into with any underwriters or agents involved in the offering or sale of any securities registered hereby may require such underwriters or dealers to indemnify the registrant, some or all of its directors and officers and its controlling persons, if any, for specified liabilities, which may include liabilities under the Securities Act of 1933, as amended.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our restated certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">II-2</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_836"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Exhibits</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.91pt">Exhibits</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Form</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">File No.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Filing</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Filed&#47;Furnished</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Herewith</font></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#8224;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form of Underwriting Agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Open Market Sale Agreement</a></font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline">SM</a></font><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">,</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">dated as of June 1, 2020, by and</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">between Precision BioSciences, Inc.</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000156459020027905/dtil-ex12_143.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">and Jefferies LLC.</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">S-3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333-238857</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6&#47;1&#47;2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519094641/d727819dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amended and Restated Certificate of</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519094641/d727819dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519094641/d727819dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporation of Precision</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519094641/d727819dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519094641/d727819dex31.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">BioSciences, Inc., dated April 1, 2019</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-38841</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4&#47;1&#47;2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017024014194/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Certificate of Amendment to</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017024014194/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017024014194/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amended and Restated Certificate of</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017024014194/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017024014194/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporation of Precision</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017024014194/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017024014194/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">BioSciences, Inc.</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-38841</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">2&#47;13&#47;2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017023072457/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amended and Restated Bylaws of</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017023072457/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000095017023072457/dtil-ex3_1.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Precision BioSciences, Inc.</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">8-K</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">001-38841</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">12&#47;22&#47;2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex41.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Specimen Certificate</a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex41.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="https://www.sec.gov/Archives/edgar/data/1357874/000119312519077399/d717633dex41.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Representing Common Stock</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">S-1&#47;A</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">333-230034</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;18&#47;2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#8224;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form of Specimen Certificate Representing Preferred Stock.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit43-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Form of Indenture.</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#8224;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form of Note.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#8224;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#8224;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant Agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#8224;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Form of Unit Agreement.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit51-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Opinion of Latham &#38; Watkins LLP</a><a href="exhibit51-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit51-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of Latham &#38; Watkins LLP (included in Exhibit 5.1).</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">23.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="exhibit232-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consent of Independent Registered</a><a href="exhibit232-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="exhibit232-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Public Accounting Firm</a><a href="exhibit232-sx3.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">24.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_78" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Powers of Attorney (incorporated by</a><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_78" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_78" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">reference to the signature page</a><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_78" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"> </a><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_78" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">hereto)</a><a href="#i5da9cf12dbf2467db14cf3ad1bcf2ded_78" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">.</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">25.1**</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Statement of Eligibility on Form T-1 under the Trust Indenture Act of 1939 of Debt Trustee (to be filed prior to any issuance of Debt Securities).</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">107*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="dtilexfilingfees.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Filing Fee Table</a></font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">*</font></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">__________________</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Filed herewith.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">To be filed by amendment or incorporated by reference in connection with the offering of the securities.</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">**</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">To be filed in accordance with the requirements of Section 305(b)(2) of the Trust Indenture Act of 1939.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">II-3</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_857"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 17. Undertakings</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The undersigned registrant hereby undertakes&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> that paragraphs (a)(1)(i), (a)(1)(ii), and (a)(1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is a part of the registration statement.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(A)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.12pt">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(B)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:4.68pt">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> that no statement made in a registration statement or prospectus that is part of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">II-4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">Any other communications that is an offer in the offering made by the undersigned registrant to the purchaser.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant&#8217;s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> offering thereof.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The undersigned registrant hereby undertakes to file an application for the purpose of determining the eligibility of the trustee to act under subsection (a) of Section 310 of the Trust Indenture Act (the &#8220;Act&#8221;) in accordance with the rules and regulations prescribed by the SEC under section 305(b)(2) of the Act.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">II-5</font></div></div></div><div id="i5da9cf12dbf2467db14cf3ad1bcf2ded_78"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Durham, State of North Carolina, on the 30</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> day of December, 2025.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">PRECISION BIOSCIENCES, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Amoroso</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Michael Amoroso</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">President, Chief Executive Officer and Director</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">II-6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><font><br></font></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">POWERS OF ATTORNEY</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Amoroso and John Alexander Kelly, or either of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place and stead, in any and all capacities, to file and sign any and all amendments, including post-effective amendments and any registration statement for the same offering that is to be effective under Rule 462(b) of the Securities Act, to this registration statement, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. This power of attorney shall be governed by and construed with the laws of the State of Delaware and applicable federal securities laws.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</font></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael Amoroso</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Michael Amoroso</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Alexander Kelly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">John Alexander Kelly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kevin Buehler</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Chair of the Board of Directors</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Kevin Buehler</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Geno Germano</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Geno Germano</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Melinda Brown</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Melinda Brown</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Stanley Frankel, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Stanley Frankel, M.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Shari Lisa Pir&#233;, J.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Director</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Shari Lisa Pir&#233;, J.D.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">II-7</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>dtilexfilingfees.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025q4">
  <head>
    <title>EX-FILING FEES</title>
  </head>
  <body>
    <div style="display: none">
      <ix:header>
        <ix:hidden>
          <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-426">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:SubmissnTp" contextRef="rc" id="ixv-427">S-3</ix:nonNumeric>
          <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="rc" id="ixv-428">EX-FILING FEES</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="rc" id="ixv-429">0001357874</ix:nonNumeric>
          <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-430">PRECISION BIOSCIENCES INC</ix:nonNumeric>
          <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"></ix:nonNumeric>
          <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ix:nonNumeric>
          <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ix:nonNumeric>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_1" id="ixv-434">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_2" id="ixv-435">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_3" id="ixv-436">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_4" id="ixv-437">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_5" id="ixv-438">0.0001381</ix:nonFraction>
          <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_6" id="ixv-439">0.0001381</ix:nonFraction>
        </ix:hidden>
        <ix:references>
          <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025q4/ffd-2025q4.xsd" xlink:type="simple"/>
        </ix:references>
        <ix:resources>
          <xbrli:context id="rc">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_1">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_2">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_3">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_4">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_5">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_6">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:context id="offrl_7">
            <xbrli:entity>
              <xbrli:identifier scheme="http://www.sec.gov/CIK">0001357874</xbrli:identifier>
              <xbrli:segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                  <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
              </xbrli:segment>
            </xbrli:entity>
            <xbrli:period>
              <xbrli:startDate>2025-12-30</xbrli:startDate>
              <xbrli:endDate>2025-12-30</xbrli:endDate>
            </xbrli:period>
          </xbrli:context>
          <xbrli:unit id="USD">
            <xbrli:measure>iso4217:USD</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="pure">
            <xbrli:measure>xbrli:pure</xbrli:measure>
          </xbrli:unit>
          <xbrli:unit id="Shares">
            <xbrli:measure>xbrli:shares</xbrli:measure>
          </xbrli:unit>
        </ix:resources>
      </ix:header>
    </div>
    <div>
      <table style="width: 99%; font-family: Arial, Helvetica, sans-serif; font-size: 20pt; text-align: center;">
        <tr>
          <td colspan="4" style="padding-bottom: .5em">
            <p>
              <b>Calculation of Filing Fee Tables</b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="ffd:FormTp" contextRef="rc" id="ixv-518">S-3</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
        <tr>
          <td style="padding-bottom: .25em">
            <p>
              <b>
                <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="rc" id="ixv-519">PRECISION BIOSCIENCES INC</ix:nonNumeric>
              </b>
            </p>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 1: Newly Registered and Carry Forward Securities</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOfferingTableNa">&#9744;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; float: center; width: 100%; text-align: center; border: 1px solid black; font-size: 16px;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 12%;">
            <!-- BLANK -->
          </th>
          <th style="width: 2%;">
            <!-- BLANK -->
          </th>
          <th style="width: 12%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 14%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title </b>
            </p>
          </th>
          <th style="width: 2%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Calculation or Carry Forward Rule</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount Registered</b>
            </p>
          </th>
          <th style="width: 15%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Proposed Maximum Offering Price Per Unit</b>
            </p>
          </th>
          <th style="width: 10%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price</b>
            </p>
          </th>
          <th style="width: 5%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Fee Rate</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Registration Fee</b>
            </p>
          </th>
          <th style="width: 1%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Form Type</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward File Number</b>
            </p>
          </th>
          <th style="width: 6%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Carry Forward Initial Effective Date</b>
            </p>
          </th>
          <th style="width: 7%;">
            <p style="margin: 0pt; text-align: center;">
              <b>Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward</b>
            </p>
          </th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Newly Registered Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_1" id="ixv-520">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_1" id="ixv-521">Common Stock, $0.000005 par value per share</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_1" format="ixt:booleantrue" id="ixv-522">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_2" id="ixv-523">Equity</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_2" id="ixv-524">Preferred Stock, $0.0001 par value per share</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_2" format="ixt:booleantrue" id="ixv-525">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_3" id="ixv-526">Debt</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_3" id="ixv-527">Debt Securities</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_3" format="ixt:booleantrue" id="ixv-528">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_4" id="ixv-529">Other</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_4" id="ixv-530">Depositary Shares</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_4" format="ixt:booleantrue" id="ixv-531">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_5" id="ixv-532">Other</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_5" id="ixv-533">Warrants</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_5" format="ixt:booleantrue" id="ixv-534">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">
            <span style="text-indent: 0px; display:inline-block; padding-left: 20px;">
              <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_6" id="ixv-535">Other</ix:nonNumeric>
            </span>
          </td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="offrl_6" id="ixv-536">Units</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_6" format="ixt:booleantrue" id="ixv-537">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="offrl_7" format="ixt:booleanfalse" id="ixv-538">Fees to be Paid</ix:nonNumeric>
          </td>
          <td style="text-align: center;">
		1
	</td>
          <td style="text-align: left;">
            <ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="offrl_7" id="ixv-539">Unallocated (Universal) Shelf</ix:nonNumeric>
          </td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">
            <ix:nonNumeric name="ffd:Rule457oFlg" contextRef="offrl_7" format="ixt:booleantrue" id="ixv-540">457(o)</ix:nonNumeric>
          </td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-541">250,000,000.00</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="7" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-542">0.0001381</ix:nonFraction>
          </td>
          <td style="text-align: right;">
            <span>$</span>
            <ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="2" format="ixt:numdotdecimal" contextRef="offrl_7" id="ixv-543">34,525.00</ix:nonFraction>
          </td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fees Previously Paid
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Carry Forward Securities</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Carry Forward Securities
	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: left;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: right;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: center;">

	</td>
          <td style="text-align: right;">

	</td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">Total Offering Amounts:</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; width: 16%;">
            <p id="MaxAggtOfferingPrice" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-544">250,000,000.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top; border-bottom: 1px black; width: 16%;">
            <p id="TotalFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-545">34,525.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fees Previously Paid:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalPreviouslyPaidAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlPrevslyPdAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-546">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Total Fee Offsets:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="TotalOffsetAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-547">0.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
        <tr>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td colspan="3" style="vertical-align: top">
            <p style="margin: 0pt; text-align: right">
					Net Fee Due:
				</p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td style="vertical-align: top">
            <p id="NetFeeAmt" style="margin: 0pt; text-align: right">
              <span>$</span>
              <ix:nonFraction name="ffd:NetFeeAmt" contextRef="rc" decimals="2" format="ixt:numdotdecimal" unitRef="USD" id="ixv-548">34,525.00</ix:nonFraction>
            </p>
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
          <td>
            <!-- BLANK -->
          </td>
        </tr>
      </table>
    </div>
    <div>
      <table style="width: 100%; text-indent: 0px;">
        <tbody>
          <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
            <td>
              <p style="margin:0pt;text-align:left; margin-bottom: 5px;">
                <b>Offering Note</b>
              </p>
            </td>
            <td/>
          </tr>
        </tbody>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="width: 100%; text-indent: 0px;">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; vertical-align: top;">
          <td style="width:10pt;">
            <p style="margin:0pt;text-align:left;">
              <sup style="vertical-align:top;line-height:120%;font-size:10px">1</sup>
            </p>
          </td>
          <td colspan="7" style="white-space: pre-line;">
            <ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="offrl_7" id="ixv-549">1. An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities.

2. Includes rights to acquire common stock or preferred stock of the Company under any shareholder rights plan then in effect, if applicable under the terms of any such plan.

3. Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities, depositary shares or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $250,000,000.

4. The proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

5. The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended.

</ix:nonNumeric>
          </td>
        </tr>
        <tr>
          <td colspan="7">
            <hr style="width:100%;text-align:left;margin-left:0"/>
          </td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 2: Fee Offset Claims and Sources</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcOffsetTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; text-align: center;  border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 10%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 8%; text-align: left;">
            <!-- BLANK -->
          </th>
          <th style="width: 16%;">
				Registrant or Filer Name
			</th>
          <th style="width: 6%;">
				Form or Filing Type
			</th>
          <th style="width: 7%;">
				File Number
			</th>
          <th style="width: 6%;">
				Initial Filing Date
			</th>
          <th style="width: 6%;">
				Filing Date
			</th>
          <th style="width: 6%;">
				Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Security Type Associated with Fee Offset Claimed
			</th>
          <th style="width: 8%;">
				Security Title Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Unsold Securities Associated with Fee Offset Claimed
			</th>
          <th style="width: 9%;">
				Unsold Aggregate Offering Amount Associated with Fee Offset Claimed
			</th>
          <th style="width: 6%;">
				Fee Paid with Fee Offset Source
			</th>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rules 457(b) and 0-11(a)(2)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr>
          <td colspan="14" style="text-align: center">
            <b>Rule 457(p)</b>
          </td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Claims
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
        <tr style="background-color:#E7E7E2">
          <td style="text-align: left;">
		Fee Offset Sources
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: left;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
        </tr>
      </table>
    </div>
    <div style="padding-bottom: 20px;">
      <table style="float: center; width: 100%; text-align: left;  ">
        <tr style="font-family: Arial, Helvetica, sans-serif; font-size: 16px">
          <th style="vertical-align: bottom; text-align: left; word-wrap: break-word">
            <b>Table 3: Combined Prospectuses</b>
          </th>
          <th style="vertical-align: bottom; word-wrap: break-word; text-align: right;">
            <span style="-sec-ix-hidden: hiddenrcCombinedProspectusTableNa">&#9745;Not Applicable</span>
          </th>
        </tr>
      </table>
      <table style="font-family: Arial, Helvetica, sans-serif; font-size: 16px; float: center; width: 100%; border: 1px solid black;">
        <tr style="background-color:#9ADAF6">
          <th style="width: 4%">
            <!-- Note column -->
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Type</b>
            </p>
          </th>
          <th style="width: 25%">
            <p style="margin: 0pt; text-align: center;">
              <b>Security Class Title</b>
            </p>
          </th>
          <th style="width: 14%">
            <p style="margin: 0pt; text-align: center;">
              <b>Amount of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 18%">
            <p style="margin: 0pt; text-align: center;">
              <b>Maximum Aggregate Offering Price of Securities Previously Registered</b>
            </p>
          </th>
          <th style="width: 6%">
            <p style="margin: 0pt; text-align: center;">
              <b>Form Type</b>
            </p>
          </th>
          <th style="width: 10%">
            <p style="margin: 0pt; text-align: center;">
              <b>File Number</b>
            </p>
          </th>
          <th style="width: 8%">
            <p style="margin: 0pt; text-align: center;">
              <b>Initial Effective Date</b>
            </p>
          </th>
        </tr>
        <tr style="background-color:#E7E7E2;">
          <td style="text-align: center;">
		N/A
	</td>
          <td>
		N/A
	</td>
          <td>
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: right;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
          <td style="text-align: center;">
		N/A
	</td>
        </tr>
      </table>
    </div>
  </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>3
<FILENAME>exhibit43-sx3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="icc36c5d2be824a158fed4ffa122b7147_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.3</font></div></div><div style="margin-bottom:135pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">PRECISION BIOSCIENCES, INC.</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">INDENTURE</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Dated as of ___________, 20___</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">&#91;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#93;</font></div><div style="margin-bottom:72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Trustee</font></div><div style="margin-bottom:72pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="icc36c5d2be824a158fed4ffa122b7147_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Page</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Definitions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">1</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Other Definitions.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Incorporation by Reference of Trust Indenture Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">5</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 1.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Rules of Construction.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE II. THE SECURITIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Issuable in Series.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Establishment of Terms of Series of Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Execution and Authentication.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">9</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Registrar, Paying Agent and Notice Agent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.5. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Paying Agent to Hold Money in Trust.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.6. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Holder Lists.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.7. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Transfer and Exchange.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">11</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.8. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Mutilated, Destroyed, Lost and Stolen Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">12</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.9. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Outstanding Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">13</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.10. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Treasury Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">13</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.11. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Temporary Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">13</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.12. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Cancellation.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.13. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Defaulted Interest.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.14. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Global Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">14</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 2.15. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">CUSIP Numbers.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">16</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE III. REDEMPTION</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Notice to Trustee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Selection of Securities to be Redeemed.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Notice of Redemption.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">17</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Effect of Notice of Redemption.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">18</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.5. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Deposit of Redemption Price.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">18</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 3.6. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Securities Redeemed in Part.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IV. COVENANTS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Payment of Principal and Interest.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">SEC Reports.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Compliance Certificate.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">19</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 4.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Stay, Extension and Usury Laws.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">20</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">i</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE V. SUCCESSORS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">20</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">When Company May Merge, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">20</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 5.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Successor Corporation Substituted.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">21</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VI. DEFAULTS AND REMEDIES</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">21</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Events of Default.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">21</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Acceleration of Maturity&#59; Rescission and Annulment.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">22</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Collection of Indebtedness and Suits for Enforcement by Trustee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">23</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Trustee May File Proofs of Claim.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">24</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.5. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Trustee May Enforce Claims Without Possession of Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">24</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.6. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Application of Money Collected.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">25</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.7. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Limitation on Suits.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">25</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.8. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Unconditional Right of Holders to Receive Principal and Interest.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.9. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Restoration of Rights and Remedies.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.10. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Rights and Remedies Cumulative.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.11. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Delay or Omission Not Waiver.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">26</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.12. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Control by Holders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.13. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Waiver of Past Defaults.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 6.14. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Undertaking for Costs.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">27</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VII. TRUSTEE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Duties of Trustee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">28</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Rights of Trustee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">29</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Individual Rights of Trustee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">30</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Trustee&#8217;s Disclaimer.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.5. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Notice of Defaults.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.6. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Reports by Trustee to Holders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.7. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Compensation and Indemnity.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.8. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Replacement of Trustee.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">32</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.9. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Successor Trustee by Merger, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">33</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.10. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Eligibility&#59; Disqualification.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">33</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 7.11. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Preferential Collection of Claims Against Company.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">34</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE VIII. SATISFACTION AND DISCHARGE&#59; DEFEASANCE</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">34</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Satisfaction and Discharge of Indenture.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">34</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Application of Trust Funds&#59; Indemnification.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">35</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Legal Defeasance of Securities of any Series.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">36</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Covenant Defeasance.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">37</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.5. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Repayment to Company.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 8.6. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Reinstatement.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">38</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">ii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE IX. AMENDMENTS AND WAIVERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">39</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Without Consent of Holders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">39</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">With Consent of Holders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">40</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Limitations.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">40</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Compliance with Trust Indenture Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.5. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Revocation and Effect of Consents.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.6. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Notation on or Exchange of Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">41</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 9.7. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Trustee Protected.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">42</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE X. MISCELLANEOUS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Trust Indenture Act Controls.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Notices.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">42</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Communication by Holders with Other Holders.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">43</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.4. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Certificate and Opinion as to Conditions Precedent.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.5. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Statements Required in Certificate or Opinion.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.6. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Rules by Trustee and Agents.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.7. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Legal Holidays.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">44</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.8. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">No Recourse Against Others.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 10.9. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Counterparts.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.10. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Governing Law&#59; Waiver of Jury Trial&#59; Consent to Jurisdiction.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">45</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.11. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">No Adverse Interpretation of Other Agreements.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.12. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Successors.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.13. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Severability.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.14. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Table of Contents, Headings, Etc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.15. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Securities in a Foreign Currency.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">46</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.16. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Judgment Currency.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">47</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.17. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Force Majeure.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">47</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.015em;line-height:100%">Section 10.18. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">U.S.A. Patriot Act.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">48</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">ARTICLE XI. SINKING FUNDS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.1. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Applicability of Article.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.2. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Satisfaction of Sinking Fund Payments with Securities.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">48</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Section 11.3. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Redemption of Securities for Sinking Fund.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">49</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iii</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">PRECISION BIOSCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Reconciliation and tie between Trust Indenture Act of 1939 and</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indenture, dated as of ____________, 20__</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 310(a)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)(3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)(4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)(5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 311(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.11</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 312(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 313(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 314(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">4.2, 10.5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)(3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Not Applicable</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 315(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">7.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.14</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 316(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)(1)(A)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.12</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)(1)(B)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.13</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 317(a)(1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(a)(2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#167; 318(a)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.1</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">__________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;letter-spacing:-0.005em;line-height:120%">Note&#58;  This reconciliation and tie shall not, for any purpose, be deemed to be part of the Indenture.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">iv</font></div></div></div><div id="icc36c5d2be824a158fed4ffa122b7147_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Indenture dated as of __________, 20__ between Precision BioSciences, Inc., a company incorporated under the laws of Delaware (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and &#91;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Each party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE I.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">DEFINITIONS AND INCORPORATION BY REFERENCE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Additional Amounts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any additional amounts which are required hereby or by any Security, under circumstances specified herein or therein, to be paid by the Company in respect of certain taxes imposed on Holders specified herein or therein and which are owing to such Holders.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any specified person means any other person directly or indirectly controlling or controlled by or under common control with such specified person.   For the purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, the terms &#8220;controlled by&#8221; and &#8220;under common control with&#8221;), as used with respect to any person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such person, whether through the ownership of voting securities or by agreement or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Registrar, Paying Agent or Notice Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Board of Directors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the board of directors of the Company or any duly authorized committee thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Board Resolution</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a copy of a resolution certified by the Secretary or an Assistant Secretary of the Company to have been adopted by the Board of Directors or pursuant to authorization by the Board of Directors and to be in full force and effect on the date of the certificate and delivered to the Trustee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day except a Saturday, Sunday or a legal holiday in the City of New York, New York (or in connection with any payment, the place of payment) on which banking institutions are authorized or required by law, regulation or executive order to close.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Capital Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the party named as such above until a successor replaces it and thereafter means the successor.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Company Order</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a written order signed in the name of the Company by an Officer and delivered to the Trustee.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Corporate Trust Office</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the office of the Trustee at which at any particular time its corporate trust business related to this Indenture shall be principally administered.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Default</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any event which is, or after notice, passage of time or both would be, an Event of Default.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Depositary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to the Securities of any Series issuable or issued in whole or in part in the form of one or more Global Securities, the person designated as Depositary for such Series by the Company, which Depositary shall be a clearing agency registered under the Exchange Act&#59; and if at any time there is more than one such person, &#8220;Depositary&#8221; as used with respect to the Securities of any Series shall mean the Depositary with respect to the Securities of such Series.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Discount Security</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Security that provides for an amount less than the stated principal amount thereof to be due and payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">$</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the currency of the United States of America.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any currency or currency unit issued by a government other than the government of the United States of America.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Foreign Government Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, with respect to Securities of any Series that are denominated in a Foreign Currency, direct obligations of, or obligations guaranteed by, the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;GAAP&#8221;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> means generally accepted accounting principles in the United States of America set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant segment of the accounting profession, which are in effect as of the date of determination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Global Security</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Global Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Security or Securities, as the case may be, in the form established pursuant to Section 2.2 evidencing all or part of a Series of Securities, issued to the Depositary for such Series or its nominee, and registered in the name of such Depositary or nominee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Holder</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a person in whose name a Security is registered on the Registrar&#8217;s books.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Indenture</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means this Indenture as amended or supplemented from time to time and shall include the form and terms of particular Series of Securities established as contemplated hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">interest</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; with respect to any Discount Security which by its terms bears interest only after Maturity, means interest payable after Maturity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Maturity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; when used with respect to any Security, means the date on which the principal of such Security becomes due and payable as therein or herein provided, whether at the Stated Maturity or by declaration of acceleration, call for redemption or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Officer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Chief Executive Officer, President, the Chief Financial Officer, the Treasurer or any Assistant Treasurer, the Secretary or any Assistant Secretary and any Vice President of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Officer&#8217;s Certificate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a certificate signed by any Officer that meets the requirements of this Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Opinion of Counsel</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a written opinion of legal counsel who is acceptable to the Trustee.  The counsel may be an employee of or counsel to the Company. The opinion may contain customary limitations, conditions and exceptions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any individual, corporation, partnership, joint venture, association, limited liability company, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">principal</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of a Security means the principal of the Security plus, when appropriate, the premium, if any, on, and any Additional Amounts in respect of, the Security.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Responsible Officer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any officer of the Trustee in its Corporate Trust Office having responsibility for administration of this Indenture and also means, with respect to a particular corporate trust matter, any other officer to whom any corporate trust matter is referred because of his or her knowledge of and familiarity with a particular subject.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities and Exchange Commission.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Security</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the debentures, notes or other debt instruments of the Company of any Series authenticated and delivered under this Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Series</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Series of Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means each series of debentures, notes or other debt instruments of the Company created pursuant to Sections 2.1 and 2.2 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Stated Maturity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; when used with respect to any Security, means the date specified in such Security as the fixed date on which the principal of such Security or interest is due and payable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of any specified person means any corporation, association or other business entity of which more than 50% of the total voting power of shares of Capital Stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such person or one or more of the other Subsidiaries of that person or a combination thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">TIA</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Trust Indenture Act of 1939 (15 U.S. Code &#167;&#167; 77aaa-77bbbb) as in effect on the date of this Indenture&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that in the event the Trust Indenture Act of 1939 is amended after such date, &#8220;TIA&#8221; means, to the extent required by any such amendment, the Trust Indenture Act as so amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the person named as the &#8220;Trustee&#8221; in the first paragraph of this instrument until a successor Trustee shall have become such pursuant to the applicable provisions of this Indenture, and thereafter &#8220;Trustee&#8221; shall mean or include each person who is then a Trustee hereunder, and if at any time there is more than one such person, &#8220;Trustee&#8221; as used with respect to the Securities of any Series shall mean the Trustee with respect to Securities of that Series.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">U.S. Government Obligations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means securities which are direct obligations of, or guaranteed by, the United States of America for the payment of which its full faith and credit is pledged and which are not callable or redeemable at the option of the issuer thereof and shall also include a depositary receipt issued by a bank or trust company as custodian with respect to any such U.S. Government Obligation or a specific payment of interest on or principal of any such U.S. Government Obligation held by such custodian for the account of the holder of a depositary receipt, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> that (except as required by law) such custodian is not authorized to make any deduction from the amount payable to the holder of such depositary receipt from any amount received by the custodian in respect of the U.S. Government Obligation evidenced by such depositary receipt.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Other Definitions</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.307%"><tr><td style="width:1.0%"></td><td style="width:50.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">TERM</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">DEFINED IN SECTION</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Agent Member</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.14.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Bankruptcy Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Custodian</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">6.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Judgment Currency</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">mandatory sinking fund payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">New York Banking Day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Notice Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">optional sinking fund payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">11.1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Paying Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Registrar</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">2.4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Required Currency</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.16</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Specified Courts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">10.10</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">successor person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">5.1</font></td></tr></table></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation by Reference of Trust Indenture Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Whenever this Indenture refers to a provision of the TIA, the provision is incorporated by reference in and made a part of this Indenture.  The following TIA terms used in this Indenture have the following meanings&#58;</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the SEC.</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">indenture securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Securities.</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">indenture security holder</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a Holder.</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">indenture to be qualified</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means this Indenture.</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">indenture trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">institutional trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the Trustee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">obligor</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; on the indenture securities means the Company and any successor obligor upon the Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All other terms used in this Indenture that are defined by the TIA, defined by TIA reference to another statute or defined by SEC rule under the TIA and not otherwise defined herein are used herein as so defined.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rules of Construction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Unless the context otherwise requires&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a term has the meaning assigned to it&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;an accounting term not otherwise defined has the meaning assigned to it in accordance with GAAP&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">or</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is not exclusive&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;words in the singular include the plural, and in the plural include the singular&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;provisions apply to successive events and transactions&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;in the computation of periods of time from a specified date to a later specified date, the word &#8220;from&#8221; means &#8220;from and including,&#8221; and the words &#8220;to&#8221; and &#8220;until&#8221; each mean &#8220;to but excluding&#8221;&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the phrase &#8220;in writing&#8221; as used herein shall be deemed to include PDFs, e-mails and other electronic means of transmission, unless otherwise indicated.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE II.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">THE SECURITIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Issuable in Series</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate principal amount of Securities that may be authenticated and delivered under this Indenture is unlimited.  The Securities may be issued in one or more Series. All Securities of a Series shall be identical except as may be set forth or determined in the manner provided in a Board Resolution, a supplemental indenture or an Officer&#8217;s Certificate detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution. In the case of Securities of a Series to be issued from time to time, the Board Resolution, Officer&#8217;s Certificate or supplemental indenture detailing the adoption of the terms thereof pursuant to authority granted under a Board Resolution may provide for the method by which specified terms (such as interest rate, maturity date, record date or date from which interest shall accrue) are to be determined.  Securities may differ between Series in respect of any matters, provided that all Series of Securities shall be equally and ratably entitled to the benefits of the Indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Establishment of Terms of Series of Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">At or prior to the issuance of any Securities within a Series, the following shall be established (as to the Series generally, in the case of Subsection 2.2.1 and either as to such Securities within the Series or as to the Series generally in the case of Subsections 2.2.2 through </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.23) by or pursuant to a Board Resolution, and set forth or determined in the manner provided in a Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.1.&#160;&#160;&#160;&#160;the title (which shall distinguish the Securities of that particular Series from the Securities of any other Series) and ranking (including the terms of any subordination provisions) of the Series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.2.&#160;&#160;&#160;&#160;the price or prices (expressed as a percentage of the principal amount thereof) at which the Securities of the Series will be issued&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.3.&#160;&#160;&#160;&#160;any limit upon the aggregate principal amount of the Securities of the Series which may be authenticated and delivered under this Indenture (except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities of the Series pursuant to Section 2.7, 2.8, 2.11, 3.6 or 9.6)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.4.&#160;&#160;&#160;&#160;the date or dates on which the principal of the Securities of the Series is payable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.5.&#160;&#160;&#160;&#160;the rate or rates (which may be fixed or variable) per annum or, if applicable, the method used to determine such rate or rates (including, but not limited to, any commodity, commodity index, stock exchange index or financial index) at which the Securities of the Series shall bear interest, if any, the date or dates from which such interest, if any, shall accrue, the date or dates on which such interest, if any, shall commence and be payable and any regular record date for the interest payable on any interest payment date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.6.&#160;&#160;&#160;&#160;the place or places where the principal of and interest, if any, on the Securities of the Series shall be payable, where the Securities of such Series may be surrendered for registration of transfer or exchange and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered, and the method of such payment, if by wire transfer, mail or other means&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.7.&#160;&#160;&#160;&#160;if applicable, the period or periods within which, the price or prices at which and the terms and conditions upon which the Securities of the Series may be redeemed, in whole or in part, at the option of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.8.&#160;&#160;&#160;&#160;the obligation, if any, of the Company to redeem or purchase the Securities of the Series pursuant to any sinking fund or analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or prices at which and the terms and conditions upon which Securities of the Series shall be redeemed or purchased, in whole or in part, pursuant to such obligation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.9.&#160;&#160;&#160;&#160;the dates, if any, on which and the price or prices at which the Securities of the Series will be repurchased by the Company at the option of the Holders thereof and other detailed terms and provisions of such repurchase obligations&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.10.&#160;&#160;&#160;&#160;if other than denominations of $1,000 and any integral multiple thereof, the denominations in which the Securities of the Series shall be issuable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.11.&#160;&#160;&#160;&#160;the forms of the Securities of the Series and whether the Securities will be issuable as Global Securities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.12.&#160;&#160;&#160;&#160;if other than the principal amount thereof, the portion of the principal amount of the Securities of the Series that shall be payable upon declaration of acceleration of the maturity thereof pursuant to Section 6.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.13.&#160;&#160;&#160;&#160;the currency of denomination of the Securities of the Series, which may be Dollars or any Foreign Currency, and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.14.&#160;&#160;&#160;&#160;the designation of the currency, currencies or currency units in which payment of the principal of and interest, if any, on the Securities of the Series will be made&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.15.&#160;&#160;&#160;&#160;if payments of principal of or interest, if any, on the Securities of the Series are to be made in one or more currencies or currency units other than that or those in which such Securities are denominated, the manner in which the exchange rate with respect to such payments will be determined&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.16.&#160;&#160;&#160;&#160;the manner in which the amounts of payment of principal of or interest, if any, on the Securities of the Series will be determined, if such amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.17.&#160;&#160;&#160;&#160;the provisions, if any, relating to any security provided for the Securities of the Series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.18.&#160;&#160;&#160;&#160;any addition to, deletion of or change in the Events of Default which applies to any Securities of the Series and any change in the right of the Trustee or the requisite Holders of such Securities to declare the principal amount thereof due and payable pursuant to Section 6.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.19.&#160;&#160;&#160;&#160;any addition to, deletion of or change in the covenants applicable to Securities of the Series&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.20.&#160;&#160;&#160;&#160;any Depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect to Securities of such Series if other than those appointed herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.21.&#160;&#160;&#160;&#160;the provisions, if any, relating to conversion or exchange of any Securities of such Series, including if applicable, the conversion or exchange price, the conversion or exchange period, provisions as to whether conversion or exchange will be mandatory, at the option of the Holders thereof or at the option of the Company, the events </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">requiring an adjustment of the conversion price or exchange price and provisions affecting conversion or exchange if such Series of Securities are redeemed&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.22.&#160;&#160;&#160;&#160;any other terms of the Series (which may supplement, modify or delete any provision of this Indenture insofar as it applies to such Series), including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of Securities of that Series&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.2.23.&#160;&#160;&#160;&#160;whether any of the Company&#8217;s direct or indirect Subsidiaries will guarantee the Securities of that Series, including the terms of subordination, if any, of such guarantees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All Securities of any one Series need not be issued at the same time and may be issued from time to time, consistent with the terms of this Indenture, if so provided by or pursuant to the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate referred to above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Execution and Authentication</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">An Officer shall sign the Securities for the Company by manual, facsimile or electronic signature. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If an Officer whose signature is on a Security no longer holds that office at the time the Security is authenticated, the Security shall nevertheless be valid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A Security shall not be valid until authenticated by the manual signature of the Trustee or an authenticating agent.  The signature shall be conclusive evidence that the Security has been authenticated under this Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee shall at any time, and from time to time, authenticate Securities for original issue in the principal amount provided in the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate, upon receipt by the Trustee of a Company Order.  Each Security shall be dated the date of its authentication.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate principal amount of Securities of any Series outstanding at any time may not exceed any limit upon the maximum principal amount for such Series set forth in the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate delivered pursuant to Section 2.2, except as provided in Section 2.8.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Prior to the issuance of Securities of any Series, the Trustee shall have received and (subject to Section 7.2) shall be fully protected in relying on&#58;  (a) the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate establishing the form of the Securities of that Series or of Securities within that Series and the terms of the Securities of that Series or of Securities within that Series, (b) an Officer&#8217;s Certificate complying with Sections 10.4 and 10.5, and (c) an Opinion of Counsel complying with Sections 10.4 and 10.5.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee shall have the right to decline to authenticate and deliver any Securities of such Series&#58; (a) if the Trustee, being advised by counsel, determines that such action may not be taken lawfully&#59; or (b) if the Trustee in good faith determines that such action may expose the Trustee to personal liability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee may appoint an authenticating agent acceptable to the Company to authenticate Securities.  An authenticating agent may authenticate Securities whenever the Trustee may do so.  Each reference in this Indenture to authentication by the Trustee includes authentication by such agent.  An authenticating agent has the same rights as an Agent to deal with the Company or an Affiliate of the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Registrar, Paying Agent and Notice Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall maintain, with respect to each Series of Securities, at the place or places specified with respect to such Series pursuant to Section 2.2, an office or agency where Securities of such Series may be presented or surrendered for payment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Paying Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), where Securities of such Series may be surrendered for registration of transfer or exchange (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Registrar</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and where notices and demands to or upon the Company in respect of the Securities of such Series and this Indenture may be delivered (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Notice Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Registrar shall keep a register with respect to each Series of Securities and to their transfer and exchange.  The Company will give prompt written notice to the Trustee of the name and address, and any change in the name or address, of each Registrar, Paying Agent or Notice Agent.  If at any time the Company shall fail to maintain any such required Registrar, Paying Agent or Notice Agent or shall fail to furnish the Trustee with the name and address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that any appointment of the Trustee as the Notice Agent shall exclude the appointment of the Trustee or any office of the Trustee as an agent to receive the service of legal process on the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company may also from time to time designate one or more co-registrars, additional paying agents or additional notice agents and may from time to time rescind such designations&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that no such designation or rescission shall in any manner relieve the Company of its obligations to maintain a Registrar, Paying Agent and Notice Agent in each place so specified pursuant to Section 2.2 for Securities of any Series for such purposes.  The Company will give prompt written notice to the Trustee of any such designation or rescission and of any change in the name or address of any such co-registrar, additional paying agent or additional notice agent.  The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Registrar</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; includes any co-registrar&#59; the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Paying Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; includes any additional paying agent&#59; and the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Notice Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; includes any additional notice agent.  The Company or any of its Affiliates may serve as Registrar or Paying Agent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company hereby appoints the Trustee the initial Registrar, Paying Agent and Notice Agent for each Series unless another Registrar, Paying Agent or Notice Agent, as the case may be, is appointed prior to the time Securities of that Series are first issued.  The rights, powers, duties, obligations and actions of each Agent under this Indenture are several and not joint or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">joint and several, and the Agents shall only be obliged to perform those duties expressly set out in this Indenture and shall have no implied duties.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Paying Agent to Hold Money in Trust</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall require each Paying Agent other than the Trustee to agree in writing that the Paying Agent will hold in trust, for the benefit of Holders of any Series of Securities or the Trustee, all money held by the Paying Agent for the payment of principal of or interest on the Series of Securities and will notify the Trustee in writing of any default by the Company in making any such payment.  While any such default continues, the Trustee may require a Paying Agent to pay all money held by it to the Trustee.  The Company at any time may require a Paying Agent to pay all money held by it to the Trustee.  Upon payment over to the Trustee, the Paying Agent (if other than the Company or a Subsidiary of the Company) shall have no further liability for the money.  If the Company or a Subsidiary of the Company acts as Paying Agent, it shall segregate and hold in a separate trust fund for the benefit of Holders of any Series of Securities all money held by it as Paying Agent.  Upon any bankruptcy, reorganization or similar proceeding with respect to the Company, the Trustee shall serve as Paying Agent for the Securities. For the avoidance of doubt, a Paying Agent and the Trustee shall be held harmless and have no liability with respect to payments or disbursements (including to the Holders) until they have confirmed receipt of funds sufficient to make the relevant payment.  No money held by an Agent needs to be segregated except as is required by law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Holder Lists</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If it is serving as Registrar, the Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of Holders of each Series of Securities and shall otherwise comply with TIA  &#167; 312(a).  If the Trustee is not the Registrar, the Company shall furnish to the Trustee at least ten days before each interest payment date and at such other times as the Trustee may request in writing a list, in such form and as of such date as the Trustee may reasonably require, of the names and addresses of Holders of each Series of Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Every Holder, by receiving and holding Securities, agrees with the Company and the Trustee that neither the Company nor the Trustee or any agent of either of them shall be held accountable by reason of the disclosure of any such information as to the names and addresses of the Holders in accordance with TIA &#167;&#160;312, regardless of the source from which such information was derived, and that the Trustee shall not be held accountable by reason of mailing any material pursuant to a request made under TIA &#167;&#160;312(b).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer and Exchange</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Where Securities of a Series are presented to the Registrar or a co-registrar with a request to register a transfer or to exchange them for an equal principal amount of Securities of the same Series, the Registrar shall register the transfer or make the exchange if its requirements for such transactions are met.  To permit registrations of transfers and exchanges, the Trustee shall authenticate Securities at the Registrar&#8217;s request.  No service charge shall be made for any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">registration of transfer or exchange (except as otherwise expressly permitted herein), but the Company may require payment of a sum sufficient to cover any transfer tax or similar governmental charge payable in connection therewith (other than any such transfer tax or similar governmental charge payable upon exchanges pursuant to Sections 2.11, 3.6 or 9.6).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Neither the Company nor the Registrar shall be required (a) to issue, register the transfer of or exchange Securities of any Series for the period beginning at the opening of business 15 days immediately preceding the sending of a notice of redemption of Securities of that Series selected for redemption and ending at the close of business on the day such notice is sent, (b) to register the transfer of or exchange Securities of any Series selected, called or being called for redemption as a whole or the portion being redeemed of any such Securities selected, called or being called for redemption in part or (c) to register the transfer of or exchange Securities of any Series between a record date and payment date for such Series of Securities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Mutilated, Destroyed, Lost and Stolen Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If any mutilated Security is surrendered to the Trustee, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefor a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If there shall be delivered to the Company and the Trustee (i) evidence to their satisfaction of the destruction, loss or theft of any Security and (ii) such security or indemnity bond as may be required by each of them to hold itself and any of its agents harmless, then, in the absence of notice to the Company or the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and upon receipt of a Company Order the Trustee shall authenticate and make available for delivery, in lieu of any such destroyed, lost or stolen Security, a new Security of the same Series and of like tenor and principal amount and bearing a number not contemporaneously outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In case any such mutilated, destroyed, lost or stolen Security has become or is about to become due and payable, the Company in its discretion may, instead of issuing a new Security, pay such Security.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Upon the issuance of any new Security under this Section, the Company may require the payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses (including the fees and expenses of the Trustee) connected therewith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Every new Security of any Series issued pursuant to this Section in lieu of any destroyed, lost or stolen Security shall constitute an original additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Securities of that Series duly issued hereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The provisions of this Section are exclusive and shall preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Outstanding Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Securities outstanding at any time are all the Securities authenticated by the Trustee except for those canceled by it, those delivered to it for cancellation, those reductions in the interest on a Global Security effected by the Trustee in accordance with the provisions hereof and those described in this Section as not outstanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If a Security is replaced pursuant to Section 2.8, it ceases to be outstanding until the Trustee receives proof satisfactory to it that the replaced Security is held by a bona fide purchaser.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Paying Agent (other than the Company, a Subsidiary of the Company or an Affiliate of the Company) holds on the Maturity of Securities of a Series money sufficient to pay such Securities payable on that date, then on and after that date such Securities of the Series cease to be outstanding and interest on them ceases to accrue.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company may purchase or otherwise acquire the Securities, whether by open market purchases, negotiated transactions or otherwise.  A Security does not cease to be outstanding because the Company or an Affiliate of the Company holds the Security (but see Section 2.10 below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In determining whether the Holders of the requisite principal amount of outstanding Securities have given any request, demand, authorization, direction, notice, consent or waiver hereunder, the principal amount of a Discount Security that shall be deemed to be outstanding for such purposes shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon a declaration of acceleration of the Maturity thereof pursuant to Section 6.2.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Treasury Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In determining whether the Holders of the required principal amount of Securities of a Series have concurred in any request, demand, authorization, direction, notice, consent or waiver, Securities of a Series owned by the Company or any Affiliate of the Company shall be disregarded, except that for the purposes of determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, notice, consent or waiver only Securities of a Series that a Responsible Officer of the Trustee knows are so owned shall be so disregarded.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Temporary Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Until definitive Securities are ready for delivery, the Company may prepare and the Trustee shall authenticate temporary Securities upon a Company Order.  Temporary </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Securities shall be substantially in the form of definitive Securities but may have variations that the Company considers appropriate for temporary Securities.  Without unreasonable delay, the Company shall prepare and the Trustee upon receipt of a Company Order shall authenticate definitive Securities of the same Series and date of maturity in exchange for temporary Securities.  Until so exchanged, temporary securities shall have the same rights under this Indenture as the definitive Securities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cancellation</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company at any time may deliver Securities to the Trustee for cancellation.  The Registrar and the Paying Agent shall forward to the Trustee any Securities surrendered to them for registration of transfer, exchange or payment.  The Trustee shall cancel all Securities surrendered for transfer, exchange, payment, replacement or cancellation and shall destroy such canceled Securities (subject to the record retention requirements of the Exchange Act and the Trustee) and deliver a certificate of such cancellation to the Company upon written request of the Company.  The Company may not issue new Securities to replace Securities that it has paid or delivered to the Trustee for cancellation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Defaulted Interest</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Company defaults in a payment of interest on a Series of Securities, it shall pay the defaulted interest, plus, to the extent permitted by law, any interest payable on the defaulted interest, to the persons who are Holders of the Series on a subsequent special record date.  The Company shall fix the record date and payment date.  At least ten days before the special record date, the Company shall send to the Trustee and to each Holder of the Series a notice that states the special record date, the payment date and the amount of interest to be paid.  The Company may pay defaulted interest in any other lawful manner.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Global Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.14.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Terms of Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  A Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate shall establish whether the Securities of a Series shall be issued in whole or in part in the form of one or more Global Securities and the Depositary for such Global Security or Securities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.14.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Transfer and Exchange</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provisions to the contrary contained in Section 2.7 of the Indenture and in addition thereto, any Global Security shall be exchangeable pursuant to Section 2.7 of the Indenture for Securities registered in the names of Holders other than the Depositary for such Security or its nominee only if (i) such Depositary notifies the Company that it is unwilling or unable to continue as Depositary for such Global Security or if at any time such Depositary ceases to be a clearing agency registered under the Exchange Act, and, in either case, the Company fails to appoint a successor Depositary registered as a clearing agency under the Exchange Act within 90 days of such event or (ii) the Company executes and delivers to the Trustee an Officer&#8217;s Certificate to the effect that such Global Security shall be so exchangeable.  Any Global Security that is exchangeable pursuant to the preceding sentence shall be exchangeable for Securities registered in such names as the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Depositary shall direct in writing in an aggregate principal amount equal to the principal amount of the Global Security with like tenor and terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Except as provided in this Section 2.14.2, a Global Security may not be transferred except as a whole by the Depositary with respect to such Global Security to a nominee of such Depositary, by a nominee of such Depositary to such Depositary or another nominee of such Depositary or by the Depositary or any such nominee to a successor Depositary or a nominee of such a successor Depositary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">None of the Trustee or any Agent shall have any obligation or duty to monitor, determine or inquire as to compliance with any restrictions on transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Security (including any transfers between or among Depositary participants, members or beneficial owners in any Global Security) other than to require delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with the express requirements hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">None of the Trustee or any Agent shall have any responsibility or obligation to any beneficial owner of a Global Security, a member of, or a participant in the Depositary or other Person with respect to the accuracy of the records of the Depositary or its nominee or of any participant or member thereof, with respect to any ownership interest in any Security or with respect to the delivery to any participant, member, beneficial owner or other Person (other than the Depositary) of any notice (including any notice of optional redemption) or the payment of any amount, under or with respect to such Security.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.14.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Legends</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Any Global Security issued hereunder shall bear a legend in substantially the following form&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF THE DEPOSITARY OR A NOMINEE OF THE DEPOSITARY.  THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY, BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY OR BY THE DEPOSITARY OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In addition, so long as the Depository Trust Company (&#8220;DTC&#8221;) is the Depositary, each Global Security registered in the name of DTC or its nominee shall bear a legend in substantially the following form&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;UNLESS THIS GLOBAL SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (&#8220;DTC&#8221;), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE &#38; CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE &#38; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE &#38; CO., HAS AN INTEREST HEREIN.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.14.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acts of Holders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  The Depositary, as a Holder, may appoint agents and otherwise authorize participants to give or take any request, demand, authorization, direction, notice, consent, waiver or other action which a Holder is entitled to give or take under the Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.14.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding the other provisions of this Indenture, unless otherwise specified as contemplated by Section 2.2, payment of the principal of and interest, if any, on any Global Security shall be made to the Holder thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.14.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agent Members</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.  The registered Holder of a Security will be treated as the owner of such Security for all purposes and only registered Holders shall have rights under this Indenture and the Securities.  Members of, or participants in, the Depositary (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Agent Members</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and persons who hold beneficial interests in a Global Security through an Agent Member shall have no rights under this Indenture with respect to any Global Security held on their behalf by the Depositary.  The Depositary may be treated by the Company, the Trustee, the Paying Agent, the Registrar and any agent of the foregoing as the absolute owner of the Global Securities for all purposes whatsoever.  Notwithstanding the foregoing, nothing herein shall prevent the Company, the Trustee, the Paying Agent, the Registrar or any agent of the foregoing from giving effect to any written certification, proxy or other authorization furnished by the Depositary or impair, as between the Depositary and its Agent Members, the operation of customary practices of such Depositary governing the exercise of the rights of a Holder of a beneficial interest in any Global Security. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CUSIP Numbers</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company in issuing the Securities may use &#8220;CUSIP&#8221; numbers (if then generally in use), and, if so, the Trustee shall use &#8220;CUSIP&#8221; numbers in notices of redemption as a convenience to Holders&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the Securities or as contained in any notice of a redemption and that reliance may be placed only on the other elements of identification printed on the Securities, and any such redemption shall not be affected by any defect in or omission of such numbers.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE III.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">REDEMPTION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice to Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company may, with respect to any Series of Securities, reserve the right to redeem and pay the Series of Securities or may covenant to redeem and pay the Series of Securities or any part thereof prior to the Stated Maturity thereof at such time and on such terms as provided for in such Securities.  If a Series of Securities is redeemable and the Company wants or is obligated to redeem prior to the Stated Maturity thereof all or part of the Series of Securities pursuant to the terms of such Securities, it shall notify the Trustee in writing of the redemption date and the principal amount of the Series of Securities to be redeemed.  The Company shall give the notice at least 15 days before the redemption date (or such shorter period as may be acceptable to the Trustee).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Selection of Securities to be Redeemed</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise indicated for a particular Series by a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate, if less than all the Securities of a Series are to be redeemed, the Securities of the Series to be redeemed will be selected as follows&#58;  (a) if the Securities are in the form of Global Securities, in accordance with the procedures of the Depositary, (b) if the Securities are listed on any national securities exchange, in compliance with the requirements of the principal national securities exchange, if any, on which the Securities are listed or (c) if not otherwise provided for under clause (a) or (b) in the manner that the Trustee deems fair and appropriate, including by lot or other method, unless otherwise required by law or applicable stock exchange requirements, subject, in the case of Global Securities, to the applicable rules and procedures of the Depositary.  The Securities to be redeemed shall be selected from Securities of the Series outstanding not previously called for redemption.  Portions of the principal of Securities of the Series that have denominations larger than $1,000 may be selected for redemption.  Securities of the Series and portions of them it selected for redemption shall be in amounts of $1,000 or whole multiples of $1,000 or, with respect to Securities of any Series issuable in other denominations pursuant to Section 2.2.10, the minimum principal denomination for each Series and the authorized integral multiples thereof.  Provisions of this Indenture that apply to Securities of a Series called for redemption also apply to portions of Securities of that Series called for redemption.  Neither the Trustee nor the Paying Agent shall be liable for any selection made by it in accordance with this paragraph (including the procedures of the Depositary).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Redemption</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise indicated for a particular Series by Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate, at least 15 days but not more than 60 days before a redemption date, the Company shall send or cause to be sent by first-class mail or electronically, in accordance with the procedures of the Depositary, a notice of redemption to each Holder whose Securities are to be redeemed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The notice shall identify the Securities of the Series to be redeemed and shall state&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the redemption date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the redemption price&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the name and address of the Paying Agent&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;if any Securities are being redeemed in part, the portion of the principal amount of such Securities to be redeemed and that, after the redemption date and upon surrender of such Security, a new Security or Securities in principal amount equal to the unredeemed portion of the original Security shall be issued in the name of the Holder thereof upon cancellation of the original Security&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;that Securities of the Series called for redemption must be surrendered to the Paying Agent to collect the redemption price&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;that interest on Securities of the Series called for redemption ceases to accrue on and after the redemption date unless the Company defaults in the deposit of the redemption price&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the &#8220;CUSIP&#8221; number, if any&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;any other information as may be required by the terms of the particular Series or the Securities of a Series being redeemed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">At the Company&#8217;s request, the Trustee shall give the notice of redemption in the Company&#8217;s name and at its expense, provided, however, that the Company has delivered to the Trustee, at least 10 days (unless a shorter time shall be acceptable to the Trustee) prior to the notice date, an Officer&#8217;s Certificate requesting that the Trustee give such notice and setting forth the information to be stated in such notice and the form of such notice.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effect of Notice of Redemption</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Once notice of redemption is sent as provided in Section 3.3, Securities of a Series called for redemption become due and payable on the redemption date and at the redemption price.  Except as otherwise provided in the supplemental indenture, Board Resolution or Officer&#8217;s Certificate for a Series, a notice of redemption may not be conditional.  Upon surrender to the Paying Agent, such Securities shall be paid at the redemption price plus accrued interest to the redemption date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Deposit of Redemption Price</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">On or before 11&#58;00 a.m., New York City time, on the redemption date, the Company shall deposit with the Paying Agent money sufficient to pay the redemption price of and accrued interest, if any, on all Securities to be redeemed on that date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities Redeemed in Part</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Upon surrender of a Security that is redeemed in part, the Trustee shall authenticate for the Holder a new Security of the same Series and the same maturity equal in principal amount to the unredeemed portion of the Security surrendered.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE IV.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">COVENANTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Payment of Principal and Interest</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company covenants and agrees for the benefit of the Holders of each Series of Securities that it will duly and punctually pay the principal of and interest, if any, on the Securities of that Series in accordance with the terms of such Securities and this Indenture.  On or before 11&#58;00 a.m., New York City time, on the applicable payment date, the Company shall deposit with the Paying Agent money sufficient to pay the principal of and interest, if any, on the Securities of each Series in accordance with the terms of such Securities and this Indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SEC Reports</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee within 15 days after it files them with the SEC copies of the annual reports and of the information, documents and other reports (or copies of such portions of any of the foregoing as the SEC may by rules and regulations prescribe) which the Company is required to file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act.  The Company also shall comply with the other provisions of TIA &#167; 314(a). Reports, information and documents filed with the SEC via the EDGAR system will be deemed to be delivered to the Trustee as of the time of such filing via EDGAR for purposes of this Section 4.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Delivery of reports, information and documents to the Trustee under this Section 4.2 is for informational purposes only and the Trustee&#8217;s receipt of the foregoing shall not constitute constructive or actual notice of any information contained therein or determinable from information contained therein, including the Company&#8217;s compliance with any of the covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officer&#8217;s Certificates).  All such reports, information or documents referred to in this Section 4.2 that the Company files with the SEC via the SEC&#8217;s EDGAR system shall be deemed to be filed with the Trustee and transmitted to Holders at the time such reports, information or documents are filed via the EDGAR system (or any successor system). </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">To the extent any Securities of a Series are outstanding, the Company shall deliver to the Trustee, within 120 days after the end of each fiscal year of the Company, an Officer&#8217;s Certificate stating that a review of the activities of the Company and its Subsidiaries during the preceding fiscal year has been made under the supervision of the signing Officer with a view to determining whether the Company has kept, observed, performed and fulfilled its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">obligations under this Indenture, and further stating, as to such Officer signing such certificate, that to the best of his&#47;her knowledge the Company has kept, observed, performed and fulfilled each and every covenant contained in this Indenture and is not in default in the performance or observance of any of the terms, provisions and conditions hereof (or, if a Default or Event of Default shall have occurred, describing all such Defaults or Events of Default of which the Officer may have knowledge).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Stay, Extension and Usury Laws</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company covenants (to the extent that it may lawfully do so) that it will not at any time insist upon, plead or in any manner whatsoever claim or take the benefit or advantage of, any stay, extension or usury law wherever enacted, now or at any time hereafter in force, which may affect the covenants or the performance of this Indenture or the Securities&#59; and the Company (to the extent it may lawfully do so) hereby expressly waives all benefit or advantage of any such law and covenants that it will not, by resort to any such law, hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and permit the execution of every such power as though no such law has been enacted.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE V.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">SUCCESSORS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">When Company May Merge, Etc</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of its properties and assets to, any person (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">successor person</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Company is the surviving entity or the successor person (if other than the Company) is a corporation, partnership, trust or other entity organized and validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes by supplemental indenture the Company&#8217;s obligations on the Securities and under this Indenture&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be continuing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall deliver to the Trustee prior to the consummation of the proposed transaction an Officer&#8217;s Certificate to the foregoing effect and an Opinion of Counsel stating that the proposed transaction and any supplemental indenture comply with this Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the above, any Subsidiary of the Company may consolidate with, merge into or transfer all or part of its properties to the Company. Neither an Officer&#8217;s Certificate nor an Opinion of Counsel shall be required to be delivered in connection therewith.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successor Corporation Substituted</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Upon any consolidation or merger, or any sale, lease, conveyance or other disposition of all or substantially all of the assets of the Company in accordance with Section 5.1, the successor corporation formed by such consolidation or into or with which the Company is merged or to which such sale, lease, conveyance or other disposition is made shall succeed to, and be substituted for, and may exercise every right and power of, the Company under this Indenture with the same effect as if such successor person has been named as the Company herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that the predecessor Company in the case of a sale, conveyance or other disposition (other than a lease) shall be released from all obligations and covenants under this Indenture and the Securities.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VI.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">DEFAULTS AND REMEDIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Events of Default</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; wherever used herein with respect to Securities of any Series, means any one of the following events, unless in the establishing Board Resolution, supplemental indenture or Officer&#8217;s Certificate it is provided that such Series shall not have the benefit of said Event of Default&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;default in the payment of any interest on any Security of that Series when it becomes due and payable, and continuance of such default for a period of 30 days (unless the entire amount of such payment is deposited by the Company with the Trustee or with a Paying Agent prior to 11&#58;00 a.m., New  York City time, on the 30</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> day of such period)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;default in the payment of principal of any Security of that Series at its Maturity&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;default in the performance or breach of any covenant or warranty of the Company in this Indenture (other than defaults pursuant to paragraph (a) or (b) above or pursuant to a covenant or warranty that has been included in this Indenture solely for the benefit of a Series of Securities other than that Series), which default continues uncured for a period of 60 days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee by the Holders of at least 25% in principal amount of the outstanding Securities of that Series a written notice specifying such default or breach and requiring it to be remedied and stating that such notice is a &#8220;Notice of Default&#8221; hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Company pursuant to or within the meaning of any Bankruptcy Law&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;commences a voluntary case,</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;consents to the entry of an order for relief against it in an involuntary case,</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;consents to the appointment of a Custodian of it or for all or substantially all of its property,</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;makes a general assignment for the benefit of its creditors, or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;generally is unable to pay its debts as the same become due&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;a court of competent jurisdiction enters an order or decree under any Bankruptcy Law that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;is for relief against the Company in an involuntary case,</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;appoints a Custodian of the Company or for all or substantially all of its property, or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;orders the liquidation of the Company,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">and the order or decree remains unstayed and in effect for 60 days&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;any other Event of Default provided with respect to Securities of that Series, which is specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate, in accordance with Section 2.2.18. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Bankruptcy Law</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means title 11, U.S. Code or any similar Federal or State law for the relief of debtors.  The term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Custodian</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any receiver, trustee, assignee, liquidator or similar official under any Bankruptcy Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company will provide the Trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what action the Company is taking or proposes to take in respect thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Acceleration of Maturity&#59; Rescission and Annulment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If an Event of Default with respect to Securities of any Series at the time outstanding occurs and is continuing (other than an Event of Default referred to in Section 6.1(d) or (e)) then in every such case the Trustee or the Holders of not less than 25% in principal amount of the outstanding Securities of that Series may declare the principal amount (or, if any Securities of that Series are Discount Securities, such portion of the principal amount as may be specified in the terms of such Securities) of and accrued and unpaid interest, if any, on all of the Securities of that Series to be due and payable immediately, by a notice in writing to the Company (and to the Trustee if given by Holders), and upon any such declaration such principal amount (or specified amount) and accrued and unpaid interest, if any, shall become immediately due and payable.  If an Event of Default specified in Section 6.1(d) or (e) shall occur, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">principal amount (or specified amount) of and accrued and unpaid interest, if any, on all outstanding Securities shall </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ipso facto</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> become and be immediately due and payable without any declaration or other act on the part of the Trustee or any Holder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">At any time after such a declaration of acceleration with respect to any Series has been made and before a judgment or decree for payment of the money due has been obtained by the Trustee as hereinafter in this Article provided, the Holders of a majority in principal amount of the outstanding Securities of that Series, by written notice to the Company and the Trustee, may rescind and annul such declaration and its consequences if all Events of Default with respect to Securities of that Series, other than the non-payment of the principal and interest, if any, of Securities of that Series which have become due solely by such declaration of acceleration, have been cured or waived as provided in Section 6.13.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">No such rescission shall affect any subsequent Default or impair any right consequent thereon.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Collection of Indebtedness and Suits for Enforcement by Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company covenants that if&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;default is made in the payment of any interest on any Security when such interest becomes due and payable and such default continues for a period of 30 days,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;default is made in the payment of principal of any Security at the Maturity thereof, or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;default is made in the deposit of any sinking fund payment, if any, when and as due by the terms of a Security,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">then,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> the Company will, upon demand of the Trustee, pay to it, for the benefit of the Holders of such Securities, the whole amount then due and payable on such Securities for principal and interest and, to the extent that payment of such interest shall be legally enforceable, interest on any overdue principal and any overdue interest at the rate or rates prescribed therefor in such Securities, and, in addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Company fails to pay such amounts forthwith upon such demand, the Trustee, in its own name and as trustee of an express trust, may institute a judicial proceeding for the collection of the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may enforce the same against the Company or any other obligor upon such Securities and collect the moneys adjudged or deemed to be payable in the manner provided by law out of the property of the Company or any other obligor upon such Securities, wherever situated.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If an Event of Default with respect to any Securities of any Series occurs and is continuing, the Trustee, subject to Article VII hereof, may in its discretion proceed to protect and enforce its rights and the rights of the Holders of Securities of such Series by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this Indenture or in aid of the exercise of any power granted herein, or to enforce any other proper remedy.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee May File Proofs of Claim</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to the Company or any other obligor upon the Securities or the property of the Company or of such other obligor or their creditors, the Trustee (irrespective of whether the principal of the Securities shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand on the Company for the payment of overdue principal or interest) shall be entitled and empowered, by intervention in such proceeding or otherwise,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;to file and prove a claim for the whole amount of principal and interest owing and unpaid in respect of the Securities and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel) and of the Holders allowed in such judicial proceeding, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to collect and receive any moneys or other property payable or deliverable on any such claims and to distribute the same,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Holder to make such payments to the Trustee and, in the event that the Trustee shall consent to the making of such payments directly to the Holders, to pay to the Trustee any amount due it for the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel and any other amounts due the Trustee under Section 7.7.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Holder any plan of reorganization, arrangement, adjustment or composition affecting the Securities or the rights of any Holder thereof or to authorize the Trustee to vote in respect of the claim of any Holder in any such proceeding.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee May Enforce Claims Without Possession of Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All rights of action and claims under this Indenture or the Securities may be prosecuted and enforced by the Trustee without the possession of any of the Securities or the production thereof in any proceeding relating thereto, and any such proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">24</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">judgment shall, after provision for the payment of the compensation, reasonable expenses, disbursements and advances of the Trustee, its agents and counsel, be for the ratable benefit of the Holders of the Securities in respect of which such judgment has been recovered.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Money Collected.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any money or property collected by the Trustee pursuant to this Article shall be applied in the following order, at the date or dates fixed by the Trustee and, in case of the distribution of such money or property on account of principal or interest, upon presentation of the Securities and the notation thereon of the payment if only partially paid and upon surrender thereof if fully paid&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">First&#58;&#160;&#160;&#160;&#160;To the payment of all amounts due the Trustee under Section 7.7&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Second&#58;&#160;&#160;&#160;&#160;To the payment of the amounts then due and unpaid for principal of and interest on the Securities in respect of which or for the benefit of which such money has been collected, ratably, without preference or priority of any kind, according to the amounts due and payable on such Securities for principal and interest, respectively&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Third&#58;&#160;&#160;&#160;&#160;To the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Suits</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">No Holder of any Security of any Series shall have any right to institute any proceeding, judicial or otherwise, with respect to this Indenture, or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;such Holder has previously given written notice to the Trustee of a continuing Event of Default with respect to the Securities of that Series&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Holders of not less than 25% in principal amount of the outstanding Securities of that Series shall have made written request to the Trustee to institute proceedings in respect of such Event of Default in its own name as Trustee hereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;such Holder or Holders have offered to the Trustee indemnity or security satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by the Trustee in compliance with such request&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Trustee for 60 days after its receipt of such notice, request and offer of indemnity has failed to institute any such proceeding&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;no direction inconsistent with such written request has been given to the Trustee during such 60-day period by the Holders of a majority in principal amount of the outstanding Securities of that Series&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">25</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">it being understood, intended and expressly covenanted by the Holder of every Security with every other Holder and the Trustee that no one or more of such Holders shall have any right in any manner whatever by virtue of, or by availing of, any provision of this Indenture to affect, disturb or prejudice the rights of any other of such Holders, or to obtain or to seek to obtain priority or preference over any other of such Holders or to enforce any right under this Indenture, except in the manner herein provided and for the equal and ratable benefit of all such Holders of the applicable Series.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Unconditional Right of Holders to Receive Principal and Interest</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any other provision in this Indenture, the Holder of any Security shall have the right, which is absolute and unconditional, to receive payment of the principal of and interest, if any, on such Security on the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such Holder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restoration of Rights and Remedies</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Trustee or any Holder has instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding has been discontinued or abandoned for any reason or has been determined adversely to the Trustee or to such Holder, then and in every such case, subject to any determination in such proceeding, the Company, the Trustee and the Holders shall be restored severally and respectively to their former positions hereunder and thereafter all rights and remedies of the Trustee and the Holders shall continue as though no such proceeding had been instituted.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rights and Remedies Cumulative</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Except as otherwise provided with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities in Section 2.8, no right or remedy herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by law, be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not, to the extent permitted by law, prevent the concurrent assertion or employment of any other appropriate right or remedy.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delay or Omission Not Waiver</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">No delay or omission of the Trustee or of any Holder of any Securities to exercise any right or remedy accruing upon any Event of Default shall impair any such right or remedy or constitute a waiver of any such Event of Default or an acquiescence therein.  Every right and remedy given by this Article or by law to the Trustee or to the Holders may be exercised from time to time, and as often as may be deemed expedient, by the Trustee or by the Holders, as the case may be.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">26</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Control by Holders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Holders of a majority in principal amount of the outstanding Securities of any Series shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee, with respect to the Securities of such Series, provided that</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;such direction shall not be in conflict with any rule of law or with this Indenture,</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Trustee may take any other action deemed proper by the Trustee which is not inconsistent with such direction, </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;subject to the provisions of Section 7.1, the Trustee shall have the right to decline to follow any such direction if the Trustee in good faith shall, by a Responsible Officer of the Trustee, determine that the proceeding so directed would involve the Trustee in personal liability, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;prior to taking any action as directed under this Section 6.12, the Trustee shall be entitled to indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Waiver of Past Defaults</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Holders of not less than a majority in principal amount of the outstanding Securities of any Series may on behalf of the Holders of all the Securities of such Series, by written notice to the Trustee and the Company, waive any past Default hereunder with respect to such Series and its consequences, except a Default in the payment of the principal of or interest on any Security of such Series (provided, however, that the Holders of a majority in principal amount of the outstanding Securities of any Series may rescind an acceleration and its consequences, including any related payment default that resulted from such acceleration).  Upon any such waiver, such Default shall cease to exist, and any Event of Default arising therefrom shall be deemed to have been cured, for every purpose of this Indenture&#59; but no such waiver shall extend to any subsequent or other Default or impair any right consequent thereon.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Undertaking for Costs</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All parties to this Indenture agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered or omitted by it as Trustee, the filing by any party litigant in such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including reasonable attorneys&#8217; fees, against any party litigant in such suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant&#59; but the provisions of this Section shall not apply to any suit instituted by the Company, to any suit instituted by the Trustee, to any suit instituted by any Holder or group of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">27</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Holders, holding in the aggregate more than 10% in principal amount of the outstanding Securities of any Series, or to any suit instituted by any Holder for the enforcement of the payment of the principal of or interest on any Security on or after the Maturity of such Security, including the Stated Maturity expressed in such Security (or, in the case of redemption, on the redemption date).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VII.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">TRUSTEE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Duties of Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If an Event of Default has occurred and is continuing, the Trustee shall exercise the rights and powers vested in it by this Indenture and use the same degree of care and skill in their exercise as a prudent person would exercise or use under the circumstances in the conduct of such person&#8217;s own affairs.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Except during the continuance of an Event of Default&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Trustee need perform only those duties that are specifically set forth in this Indenture and no others, and no implied covenants or obligations will be read into this Indenture against the Trustee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon Officer&#8217;s Certificates or Opinions of Counsel furnished to the Trustee and conforming to the requirements of this Indenture&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, in the case of any such Officer&#8217;s Certificates or Opinions of Counsel which by any provisions hereof are specifically required to be furnished to the Trustee, the Trustee shall examine such Officer&#8217;s Certificates and Opinions of Counsel to determine whether or not they conform to the form requirements of this Indenture.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act or its own willful misconduct, except that&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;This paragraph does not limit the effect of paragraph (b) of this Section.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent facts.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;The Trustee shall not be liable with respect to any action taken, suffered or omitted to be taken by it with respect to Securities of any Series in good faith in accordance with the direction of the Holders of a majority in principal amount of the outstanding Securities of such Series relating to the time, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">28</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture with respect to the Securities of such Series in accordance with Section 6.12.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Every provision of this Indenture that in any way relates to the Trustee is subject to paragraph (a), (b) and (c) of this Section.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Trustee may refuse to perform any duty or exercise any right or power unless it receives indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in performing such duty or exercising such right or power.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing with the Company.  Money held in trust by the Trustee need not be segregated from other funds except to the extent required by law.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;No provision of this Indenture shall require the Trustee to risk its own funds or otherwise incur any financial liability in the performance of any of its duties or in the exercise of any of its rights or powers, if adequate indemnity against such risk is not assured to the Trustee in its satisfaction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;The Paying Agent, the Notice Agent, the Registrar, any authenticating agent and the Trustee when acting in any other capacity hereunder shall be entitled to the protections and immunities as are set forth in this Article VII.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The rights, privileges, protections, immunities and benefits given to the Trustee, including its right to be indemnified, are extended to, and will be enforceable by, the Trustee in each of its capacities under this Indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rights of Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Trustee may rely on and shall be protected in acting or refraining from acting upon any document (whether in its original or facsimile form) believed by it to be genuine and to have been signed or presented by the proper person.  The Trustee need not investigate any fact or matter stated in the document.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Before the Trustee acts or refrains from acting, it may require an Officer&#8217;s Certificate or an Opinion of Counsel or both.  The Trustee shall not be liable for any action it takes or omits to take in good faith in reliance on such Officer&#8217;s Certificate or Opinion of Counsel.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Trustee may act through agents and shall not be responsible for the misconduct or negligence of any agent appointed with due care.  No Depositary shall be deemed an agent of the Trustee, and the Trustee shall not be responsible for any act or omission by any Depositary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">29</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Trustee shall not be liable for any action it takes or omits to take in good faith which it believes to be authorized or within its rights or powers.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Trustee may consult with counsel and the advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in reliance thereon.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders of Securities unless such Holders shall have offered to the Trustee security or indemnity satisfactory to it against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;The Trustee shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document, but the Trustee, in its discretion, may make such further inquiry or investigation into such facts or matters as it may see fit.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;The Trustee shall not be deemed to have notice of any Default or Event of Default unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default is received by a Responsible Officer at the Corporate Trust Office of the Trustee, and such notice references the Securities generally or the Securities of a particular Series and this Indenture.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;In no event shall the Trustee be liable to any person for special, punitive, indirect, consequential or incidental loss or damage of any kind whatsoever (including but not limited to lost profits), even if the Trustee has been advised of the likelihood of such loss or damage.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;The permissive right of the Trustee to take the actions permitted by this Indenture shall not be construed as an obligation or duty to do so.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;The Trustee will not be required to give any bond or surety in respect of the execution of this Indenture or otherwise.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Individual Rights of Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee in its individual or any other capacity may become the owner or pledgee of Securities and may otherwise deal with the Company or an Affiliate of the Company with the same rights it would have if it were not Trustee.  Any Agent may do the same with like rights.  The Trustee is also subject to Sections 7.10 and 7.11.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">30</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee&#8217;s Disclaimer</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee makes no representation as to the validity or adequacy of this Indenture or the Securities. The Trustee shall not be accountable for the Company&#8217;s use of the proceeds from the Securities and shall not be responsible for any statement in the Securities other than its certificate of authentication.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice of Defaults</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If a Default or Event of Default occurs and is continuing with respect to the Securities of any Series and if it is known to a Responsible Officer of the Trustee, the Trustee shall send to each Holder of the Securities of that Series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a Responsible Officer of the Trustee has knowledge of such Default or Event of Default.  Except in the case of a Default or Event of Default in payment of principal of or interest on any Security of any Series, the Trustee may withhold the notice if and so long as its corporate trust committee or a committee of its Responsible Officers in good faith determines that withholding the notice is in the interests of Holders of that Series.  The Trustee will not be deemed to have notice or be charged with knowledge of any Default or Event of Default unless written notice thereof has been received by a Responsible Officer, and such notice references the applicable Series of Securities and this Indenture and states on its face that a Default or Event of Default has occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reports by Trustee to Holders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Within 60 days after each &#91;&#91;   &#93; commencing &#91;   &#93;, &#91;   &#93;&#93;, the Trustee shall transmit by mail to all Holders, as their names and addresses appear on the register kept by the Registrar, a brief report dated as of such date, in accordance with, and to the extent required under, TIA &#167; 313.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A copy of each report at the time of its mailing to Holders of any Series shall be filed with the SEC and each national securities exchange on which the Securities of that Series are listed.  The Company shall promptly notify the Trustee in writing when Securities of any Series are listed on any national securities exchange.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation and Indemnity</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall pay to the Trustee from time to time compensation for its services as the Company and the Trustee shall from time to time agree upon in writing.  The Trustee&#8217;s compensation shall not be limited by any law on compensation of a trustee of an express trust.  The Company shall reimburse the Trustee upon request for all reasonable out-of-pocket expenses incurred by it.  Such expenses shall include the reasonable compensation and expenses of the Trustee&#8217;s agents and counsel.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall indemnify each of the Trustee and any predecessor Trustee (including for the cost of defending itself) against any cost, expense or liability, including taxes (other than taxes based upon, measured by or determined by the income of the Trustee) incurred </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">31</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">by it except as set forth in the next paragraph in the performance of its duties under this Indenture as Trustee or Agent.  The Trustee shall notify the Company promptly of any claim for which it may seek indemnity.  Failure by the Trustee to so notify the Company shall not relieve the Company of its obligations hereunder, unless and to the extent that the Company is materially prejudiced thereby.  The Company shall defend the claim and the Trustee shall cooperate in the defense.  The Trustee may have separate counsel, and the Company shall pay the reasonable fees and expenses of such counsel.  The Company need not pay for any settlement made without its consent, which consent will not be unreasonably withheld.  This indemnification shall apply to officers, directors, employees, shareholders and agents of the Trustee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company need not reimburse any expense or indemnify against any loss or liability incurred by the Trustee or by any officer, director, employee, shareholder or agent of the Trustee through willful misconduct or negligence, as determined by a final decision of a court of competent jurisdiction. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">To secure the Company&#8217;s payment obligations in this Section, the Trustee shall have a lien prior to the Securities of any Series on all money or property held or collected by the Trustee, except that held in trust to pay principal of and interest on particular Securities of that Series.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">When the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.1(d) or (e) occurs, the expenses and the compensation for the services are intended to constitute expenses of administration under any Bankruptcy Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The provisions of this Section shall survive the termination of this Indenture and  the resignation or removal of the Trustee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Replacement of Trustee</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A resignation or removal of the Trustee and appointment of a successor Trustee shall become effective only upon the successor Trustee&#8217;s acceptance of appointment as provided in this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee may resign with respect to the Securities of one or more Series by so notifying the Company at least 30 days prior to the date of the proposed resignation.  The Holders of a majority in principal amount of the Securities of any Series may remove the Trustee with respect to that Series by so notifying the Trustee and the Company.  The Company may remove the Trustee with respect to Securities of one or more Series if&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the Trustee fails to comply with Section 7.10&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Trustee is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a Custodian or public officer takes charge of the Trustee or its property&#59; or</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">32</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Trustee becomes incapable of acting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Company shall promptly appoint a successor Trustee.  Within one year after the successor Trustee takes office, the Holders of a majority in principal amount of the then outstanding Securities may appoint a successor Trustee to replace the successor Trustee appointed by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If a successor Trustee with respect to the Securities of any one or more Series does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Company or the Holders of at least a majority in principal amount of the Securities of the applicable Series may petition any court of competent jurisdiction for the appointment of a successor Trustee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Company.  Immediately after that, the retiring Trustee shall transfer all property held by it as Trustee to the successor Trustee subject to the lien provided for in Section 7.7, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee with respect to each Series of Securities for which it is acting as Trustee under this Indenture.  A successor Trustee shall send a notice of its succession to each Holder of each such Series.  Notwithstanding replacement of the Trustee pursuant to this Section 7.8, the Company&#8217;s obligations under Section 7.7 hereof shall continue for the benefit of the retiring Trustee with respect to expenses and liabilities incurred by it for actions taken or omitted to be taken in accordance with its rights, powers and duties under this Indenture prior to such replacement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successor Trustee by Merger, Etc</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any organization or entity into which the Trustee may be merged or converted or with which it may be consolidated, or any organization or entity resulting from any merger,</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">conversion or consolidation to which the Trustee shall be a party, or any organization or entity succeeding to all or substantially all of the corporate trust business of the Trustee, shall be the successor of the Trustee hereunder, provided such organization or entity shall be otherwise qualified and eligible under Section 7.10, without the execution or filing of any paper or any further act on the part of any of the parties hereto.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Eligibility&#59; Disqualification</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This Indenture shall always have a Trustee who satisfies the requirements of TIA &#167; 310(a)(1), (2) and (5).  The Trustee shall always have a combined capital and surplus of at least $25,000,000 as set forth in its most recent published annual report of condition.  The Trustee shall comply with TIA &#167; 310(b).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">33</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Preferential Collection of Claims Against Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee is subject to TIA &#167; 311(a), excluding any creditor relationship listed in TIA &#167; 311(b).  A Trustee who has resigned or been removed shall be subject to TIA &#167; 311(a) to the extent indicated.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VIII.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">SATISFACTION AND DISCHARGE&#59; DEFEASANCE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Satisfaction and Discharge of Indenture</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This Indenture shall upon Company Order be discharged with respect to the Securities of any Series and cease to be of further effect as to all Securities of such Series (except as hereinafter provided in this Section 8.1), and the Trustee, at the expense of the Company, shall execute instruments acknowledging satisfaction and discharge of this Indenture, when</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;either</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;all Securities of such Series theretofore authenticated and delivered (other than Securities that have been destroyed, lost or stolen and that have been replaced or paid) have been delivered to the Trustee for cancellation&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;all such Securities of such Series not theretofore delivered to the Trustee for cancellation&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;have become due and payable by reason of sending a notice of redemption or otherwise,</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;will become due and payable at their Stated Maturity within one year,</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;have been called for redemption or are to be called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense, of the Company, or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;are deemed paid and discharged pursuant to Section 8.3, as applicable&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">and the Company, in the case of (1), (2) or (3) above, has irrevocably deposited or caused to be deposited with the Trustee as trust funds in trust an amount of money or U.S. Government Obligations, which amount shall be sufficient for the purpose of paying and discharging each installment of principal (including mandatory sinking fund payments or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal or interest are due&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">34</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the Company has paid or caused to be paid all other sums payable hereunder by the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the Company has delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the satisfaction and discharge contemplated by this Section have been complied with.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the satisfaction and discharge of this Indenture, (x) the obligations of the Company to the Trustee under Section 7.7, (y) if money shall have been deposited with the Trustee pursuant to clause (a) of this Section, the provisions of Sections 2.4, 2.7, 2.8, 8.2 and 8.5, and (z) the rights, powers, trusts and immunities of the Trustee hereunder and the Company&#8217;s obligations in connection therewith shall survive.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Application of Trust Funds&#59; Indemnification</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to the provisions of Section 8.5, all money and U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4 and all money received by the Trustee in respect of U.S. Government Obligations or Foreign Government Obligations deposited with the Trustee pursuant to Section 8.1, 8.3 or 8.4, shall be held in trust and applied by it, in accordance with the provisions of the Securities and this Indenture, to the payment, either directly or through any Paying Agent (including the Company acting as its own Paying Agent) as the Trustee may determine, to the persons entitled thereto, of the principal and interest for whose payment such money has been deposited with or received by the Trustee or to make mandatory sinking fund payments or analogous payments as contemplated by Sections 8.1, 8.3 or 8.4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company shall pay and shall indemnify the Trustee (which indemnity shall survive termination of this Indenture) against any tax, fee or other charge imposed on or assessed against U.S. Government Obligations or Foreign Government Obligations deposited pursuant to Sections 8.1, 8.3 or 8.4 or the interest and principal received in respect of such obligations other than any payable by or on behalf of Holders.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The Trustee shall deliver or pay to the Company from time to time upon Company Order any U.S. Government Obligations or Foreign Government Obligations or money held by it as provided in Sections 8.3 or 8.4 which, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, are then in excess of the amount thereof which then would have been required to be deposited for the purpose for which such U.S. Government Obligations or Foreign Government Obligations or money were deposited or received.  This provision shall not authorize the sale by the Trustee of any U.S. Government Obligations or Foreign Government Obligations held under this Indenture.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">35</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Defeasance of Securities of any Series</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Unless this Section 8.3 is otherwise specified, pursuant to Section 2.2, to be inapplicable to Securities of any Series, the Company shall be deemed to have paid and discharged the entire indebtedness on all the outstanding Securities of any Series on the 91st day after the date of the deposit referred to in subparagraph (d) hereof, and the provisions of this Indenture, as it relates to such outstanding Securities of such Series, shall no longer be in effect (and the Trustee, at the expense of the Company, shall, upon receipt of a Company Order, execute instruments acknowledging the same), except as to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the rights of Holders of Securities of such Series to receive, from the trust funds described in subparagraph (d) hereof, (i) payment of the principal of and each installment of principal of and interest on the outstanding Securities of such Series on the Maturity of such principal or installment of principal or interest and (ii) the benefit of any mandatory sinking fund payments applicable to the Securities of such Series on the day on which such payments are due and payable in accordance with the terms of this Indenture and the Securities of such Series&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;the provisions of Sections 2.4, 2.5, 2.7, 2.8, 7.7, 8.2, 8.3, 8.5 and 8.6&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;the rights, powers, trusts and immunities of the Trustee hereunder and the Company&#8217;s obligations in connection therewith&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">provided that, the following conditions shall have been satisfied&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Company shall have irrevocably deposited or caused to be deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds specifically pledged as security for and dedicated solely to the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and&#47;or U.S. Government Obligations or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and&#47;or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal of and interest, on and any mandatory sinking fund payments in respect of all the Securities of such Series on the dates such installments of principal or interest and such sinking fund payments are due&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is a party or by which it is bound&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">36</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;no Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit or during the period ending on the 91st day after such date&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel to the effect that (i) the Company has received from, or there has been published by, the Internal Revenue Service a ruling or (ii) since the date of execution of this Indenture, there has been a change in the applicable Federal income tax law, in either case to the effect that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit, defeasance and discharge and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit, defeasance and discharge had not occurred&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate stating that the deposit was not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent provided for relating to the defeasance contemplated by this Section have been complied with.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covenant Defeasance</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Unless this Section 8.4 is otherwise specified pursuant to Section 2.2 to be inapplicable to Securities of any Series, the Company may omit to comply with respect to the Securities of any Series with any term, provision or condition set forth under Sections 4.2, 4.3, 4.4 and 5.1 and, unless otherwise specified therein, any additional covenants specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 (and the failure to comply with any such covenants shall not constitute a Default or Event of Default with respect to such Series under Section 6.1) and the occurrence of any event specified in a supplemental indenture for such Series of Securities or a Board Resolution or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 and designated as an Event of Default shall not constitute a Default or Event of Default hereunder, with respect to the Securities of such Series, but, except as specified above, the remainder of this Indenture and such Securities will be unaffected thereby&#59; provided that the following conditions shall have been satisfied&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;with reference to this Section 8.4, the Company has irrevocably deposited or caused to be irrevocably deposited (except as provided in Section 8.2(c)) with the Trustee as trust funds in trust for the purpose of making the following payments specifically pledged as security for, and dedicated solely to, the benefit of the Holders of such Securities (i) in the case of Securities of such Series denominated in Dollars, cash in Dollars and&#47;or U.S. Government Obligations or (ii) in the case of Securities of such Series denominated in a Foreign Currency (other than a composite currency), money and&#47;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">37</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">or Foreign Government Obligations, which through the payment of interest and principal in respect thereof in accordance with their terms, will provide (and without reinvestment and assuming no tax liability will be imposed on such Trustee), not later than one day before the due date of any payment of money, an amount in cash, sufficient, in the opinion of a nationally recognized firm of independent certified public accountants or investment bank expressed in a written certification thereof delivered to the Trustee, to pay and discharge each installment of principal (including mandatory sinking fund payments or analogous payments) of and interest on all the Securities of such Series on the dates such installments of principal or interest are due&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;such deposit will not result in a breach or violation of, or constitute a default under, this Indenture or any other agreement or instrument to which the Company is a party or by which it is bound&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;no Default or Event of Default with respect to the Securities of such Series shall have occurred and be continuing on the date of such deposit&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;the Company shall have delivered to the Trustee an Officers&#8217; Certificate and an Opinion of Counsel to the effect that the Holders of the Securities of such Series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit and covenant defeasance and will be subject to Federal income tax on the same amount and in the same manner and at the same times as would have been the case if such deposit and covenant defeasance had not occurred&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Company shall have delivered to the Trustee an Officer&#8217;s Certificate stating the deposit was not made by the Company with the intent of defeating, hindering, delaying or defrauding any other creditors of the Company&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;The Company shall have delivered to the Trustee an Officer&#8217;s Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the covenant defeasance contemplated by this Section have been complied with.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Repayment to Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Subject to applicable abandoned property law, the Trustee and the Paying Agent shall pay to the Company upon request any money held by them for the payment of principal and interest that remains unclaimed for two years.  After that, Holders entitled to the money must look to the Company for payment as general creditors unless an applicable abandoned property law designates another person.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reinstatement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Trustee or the Paying Agent is unable to apply any money deposited with respect to Securities of any Series in accordance with Section 8.1 by reason of any legal proceeding or by reason of any order or judgment of any court or governmental authority </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">38</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">enjoining, restraining or otherwise prohibiting such application, the obligations of the Company under this Indenture with respect to the Securities of such Series and under the Securities of such Series shall be revived and reinstated as though no deposit had occurred pursuant to Section 8.1 until such time as the Trustee or the Paying Agent is permitted to apply all such money in accordance with Section 8.1&#59; </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that if the Company has made any payment of principal of or interest on or any Additional Amounts with respect to any Securities because of the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such Securities to receive such payment from the money or U.S. Government Obligations held by the Trustee or Paying Agent after payment in full to the Holders.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE IX.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">AMENDMENTS AND WAIVERS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Without Consent of Holders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company and the Trustee may amend or supplement this Indenture or the Securities of one or more Series without the consent of any Holder&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;to cure any ambiguity, defect or inconsistency&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to comply with Article V&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;to provide for uncertificated Securities in addition to or in place of certificated Securities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;to add guarantees with respect to Securities of any Series or secure Securities of any Series&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;to surrender any of the Company&#8217;s rights or powers under this Indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;to add covenants or events of default for the benefit of the holders of Securities of any Series&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;to comply with the applicable procedures of the applicable depositary&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;to make any change that does not adversely affect the rights of any Holder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;to provide for the issuance of and establish the form and terms and conditions of Securities of any Series as permitted by this Indenture&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(j)&#160;&#160;&#160;&#160;to evidence and provide for the acceptance of appointment hereunder by a successor Trustee with respect to the Securities of one or more Series and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts hereunder by more than one Trustee&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(k)&#160;&#160;&#160;&#160;to comply with requirements of the SEC in order to effect or maintain the qualification of this Indenture under the TIA.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">39</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">With Consent of Holders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Subject to Section 9.3, the Company and the Trustee may enter into a supplemental indenture with the written consent of the Holders of at least a majority in principal amount of the outstanding Securities of each Series affected by such supplemental indenture (including consents obtained in connection with a tender offer or exchange offer for the Securities of such Series), for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any supplemental indenture or of modifying in any manner the rights of the Holders of each such Series.  Except as provided in Section 6.13, and subject to Section 9.3, the Holders of at least a majority in principal amount of the outstanding Securities of any Series by notice to the Trustee (including consents obtained in connection with a tender offer or exchange offer for the Securities of such Series) may waive compliance by the Company with any provision of this Indenture or the Securities with respect to such Series.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">It shall not be necessary for the consent of the Holders of Securities under this Section 9.2 to approve the particular form of any proposed supplemental indenture or waiver, but it shall be sufficient if such consent approves the substance thereof.  After a supplemental indenture or waiver under this section becomes effective, the Company shall send to the Holders of Securities affected thereby, a notice briefly describing the supplemental indenture or waiver.  Any failure by the Company to send such notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such supplemental indenture or waiver.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Without the consent of each Holder affected, an amendment or waiver may not&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;reduce the principal amount of Securities whose Holders must consent to an amendment, supplement or waiver&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;reduce the rate of or extend the time for payment of interest (including default interest) on any Security&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;reduce the principal or change the Stated Maturity of any Security or reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;reduce the principal amount of Discount Securities payable upon acceleration of the maturity thereof&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;waive a Default or Event of Default in the payment of the principal of or interest, if any, on any Security (except a rescission of acceleration of the Securities of any Series by the Holders of at least a majority in principal amount of the outstanding Securities of such Series and a waiver of the payment default that resulted from such acceleration)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">40</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;make the principal of or interest, if any, on any Security payable in any currency other than that stated in the Security&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;make any change in Sections 6.8, 6.13 or 9.3 (this sentence)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;waive a redemption payment with respect to any Security, provided that such redemption is made at the Company&#8217;s option.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Compliance with Trust Indenture Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Every amendment to this Indenture or the Securities of one or more Series shall be set forth in a supplemental indenture hereto that complies with the TIA as then in effect.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Revocation and Effect of Consents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Until an amendment is set forth in a supplemental indenture or a waiver becomes effective, a consent to it by a Holder of a Security is a continuing consent by the Holder and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder&#8217;s Security, even if notation of the consent is not made on any Security.  However, any such Holder or subsequent Holder may revoke the consent as to his Security or portion of a Security if the Trustee receives the notice of revocation before the date of the supplemental indenture or the date the waiver becomes effective.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any amendment or waiver once effective shall bind every Holder of each Series affected by such amendment or waiver unless it is of the type described in any of clauses (a) through (h) of Section 9.3.  In that case, the amendment or waiver shall bind each Holder of a Security who has consented to it and every subsequent Holder of a Security or portion of a Security that evidences the same debt as the consenting Holder&#8217;s Security.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company may, but shall not be obligated to, fix a record date for the purpose of determining the Holders entitled to give their consent or take any other action described above or required or permitted to be taken pursuant to this Indenture. If a record date is fixed, then notwithstanding the second immediately preceding paragraph, those Persons who were Holders at such record date (or their duly designated proxies), and only those Persons, shall be entitled to give such consent or to revoke any consent previously given or take any such action, whether or not such Persons continue to be Holders after such record date. No such consent shall be valid or effective for more than 120 days after such record date.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notation on or Exchange of Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company or the Trustee may, but shall not be obligated to, place an appropriate notation about an amendment or waiver on any Security of any Series thereafter authenticated.  The Company in exchange for Securities of that Series may issue and the Trustee shall authenticate upon receipt of a Company Order in accordance with Section 2.3 new Securities of that Series that reflect the amendment or waiver.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">41</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trustee Protected</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In executing, or accepting the additional trusts created by, any supplemental indenture permitted by this Article or the modifications thereby of the trusts created by this Indenture, the Trustee shall be entitled to receive, upon request, an Officer&#8217;s Certificate and&#47;or an Opinion of Counsel complying with Sections 10.4 and 10.5 and (subject to Section 7.1) shall be fully protected in relying upon such Officer&#8217;s Certificate and&#47;or Opinion of Counsel.  The Trustee shall sign all supplemental indentures upon delivery of such an Officer&#8217;s Certificate or Opinion of Counsel or both, except that the Trustee need not sign any supplemental indenture that adversely affects its rights, duties, liabilities or immunities under this Indenture.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE X.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trust Indenture Act Controls</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If any provision of this Indenture limits, qualifies or conflicts with another provision which is required or deemed to be included in this Indenture by the TIA, such required or deemed provision shall control.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any notice or communication by the Company or the Trustee to the other, or by a Holder to the Company or the Trustee, is duly given if in writing and delivered in person or mailed by first-class mail (registered or certified, return receipt requested), email or overnight air courier guaranteeing next day delivery, to the others&#8217; address&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">if to the Company&#58;</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Precision BioSciences, Inc.</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">302 East Pettigrew St., Suite A 100</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Durham, North Carolina 27701</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; President and Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Latham &#38; Watkins LLP</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">200 Clarendon Street, 27th Floor</font></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">38 Boston, Massachusetts 02116</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Peter N. Handrinos, Esq. and Nathan Ajiashvili, Esq.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">if to the Trustee&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#93;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;_____&#93;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; &#91;____&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58; &#91;____&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">42</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">with a copy to&#58;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;_____&#93;</font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58;  &#91;____&#93;</font></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58; &#91;____&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company or the Trustee by notice to the other may designate additional or different addresses for subsequent notices or communications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any notice or communication to a Holder shall be sent electronically or by first-class mail or overnight air courier to his, her or its address shown on the register kept by the Registrar, in accordance with the procedures of the Depositary.  Failure to send a notice or communication to a Holder of any Series or any defect in it shall not affect its sufficiency with respect to other Holders of that or any other Series.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If a notice or communication is sent or published in the manner provided above, within the time prescribed, it is duly given, whether or not the Holder receives it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If the Company sends a notice or communication to Holders, it shall send a copy to the Trustee and each Agent at the same time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee shall not have any duty to confirm that the person sending any notice, instruction or other communication by electronic transmission (including by e-mail, facsimile transmission, web portal or other electronic methods) is, in fact, a person authorized to do so. Electronic signatures believed by the Trustee to comply with the ESIGN Act of 2000 or other applicable law (including electronic images of handwritten signatures and digital signatures provided by DocuSign, Orbit, Adobe Sign or any other digital signature provider acceptable to the Trustee) shall be deemed original signatures for all purposes. The Company assumes all risks arising out of the use of electronic signatures and electronic methods to send communications to the Trustee, including without limitation the risk of the Trustee acting on an unauthorized communication, and the risk of interception or misuse by third parties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding any other provision of this Indenture or any Security, where this Indenture or any Security provides for notice of any event (including any notice of redemption) to a Holder of a Global Security (whether by mail or otherwise), such notice shall be sufficiently given to the Depositary for such Security (or its designee) pursuant to the customary procedures of such Depositary. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Communication by Holders with Other Holders</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Holders of any Series may communicate pursuant to TIA &#167; 312(b) with other Holders of that Series or any other Series with respect to their rights under this Indenture or the Securities of that Series or all Series.  The Company, the Trustee, the Registrar and anyone else shall have the protection of TIA &#167; 312(c).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">43</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate and Opinion as to Conditions Precedent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Upon any request or application by the Company to the Trustee to take any action under this Indenture, the Company shall furnish to the Trustee&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;an Officer&#8217;s Certificate stating that, in the opinion of the signers, all conditions precedent, if any, provided for in this Indenture relating to the proposed action have been complied with&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Statements Required in Certificate or Opinion</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Each certificate or opinion with respect to compliance with a condition or covenant provided for in this Indenture (other than a certificate provided pursuant to TIA &#167; 314(a)(4)) shall comply with the provisions of TIA &#167; 314(e) and shall include&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;a statement that the person making such certificate or opinion has read such covenant or condition&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;a statement that, in the opinion of such person, such person has made such examination or investigation as is necessary to enable such person to express an informed opinion as to whether or not such covenant or condition has been complied with&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;a statement as to whether or not, in the opinion of such person, such condition or covenant has been complied with.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rules by Trustee and Agents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Trustee may make reasonable rules for action by or a meeting of Holders of one or more Series.  Any Agent may make reasonable rules and set reasonable requirements for its functions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Legal Holidays</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">If a payment date for any payment made under this Indenture is not a Business Day, payment may be made on the next succeeding Business Day, and no interest shall accrue for the intervening period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">44</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Recourse Against Others</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">A director, officer, employee or stockholder (past or present), as such, of the Company shall not have any liability for any obligations of the Company under the Securities or the Indenture or for any claim based on, in respect of or by reason of such obligations or their creation.  Each Holder by accepting a Security waives and releases all such liability.  The waiver and release are part of the consideration for the issue of the Securities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This Indenture may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. The exchange of copies of this Indenture and of signature pages by facsimile or electronic format (e.g., &#8220;.pdf&#8221; or &#8220;.tif&#8221;) transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile or electronic format (e.g., &#8220;.pdf&#8221; or &#8220;.tif&#8221;) shall be deemed to be their original signatures for all purposes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise provided herein or in any other Securities, the words &#8220;execute&#8221;, &#8220;execution&#8221;, &#8220;signed&#8221; and &#8220;signature&#8221; and words of similar import used in or related to any document to be signed in connection with this Indenture, any Securities or any of the transactions contemplated hereby (including amendments, waivers, consents and other modifications) shall be deemed to include electronic signatures and the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature in ink or the use of a paper-based recordkeeping system, as applicable, to the fullest extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act and any other similar state laws based on the Uniform Electronic Transactions Act.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law&#59; Waiver of Jury Trial&#59; Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">THIS INDENTURE AND THE SECURITIES, INCLUDING ANY CLAIM OR CONTROVERSY ARISING OUT OF OR RELATING TO THE INDENTURE OR THE SECURITIES, SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">THE COMPANY, THE TRUSTEE AND THE HOLDERS (BY THEIR ACCEPTANCE OF THE SECURITIES) EACH HEREBY IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE SECURITIES OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Any legal suit, action or proceeding arising out of or based upon this Indenture or the transactions contemplated hereby may be instituted in the federal courts of the United States </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">45</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">of America located in the City of New York or the courts of the State of New York in each case located in the City of New York (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Specified Courts</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and each party irrevocably submits to the non-exclusive jurisdiction of such courts in any such suit, action or proceeding.  Service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court.  The Company, the Trustee and the Holders (by their acceptance of the Securities) each hereby irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">No Adverse Interpretation of Other Agreements</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This Indenture may not be used to interpret another indenture, loan or debt agreement of the Company or a Subsidiary of the Company.  Any such indenture, loan or debt agreement may not be used to interpret this Indenture.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All agreements of the Company in this Indenture and the Securities shall bind its successor.  All agreements of the Trustee in this Indenture shall bind its successor.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In case any provision in this Indenture or in the Securities shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents, Headings, Etc</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Table of Contents, Cross Reference Table, headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms or provisions hereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Securities in a Foreign Currency</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular Series of Securities, whenever for purposes of this Indenture any action may be taken by the Holders of a specified percentage in aggregate principal amount of Securities of all Series or all Series affected by a particular action at the time outstanding and, at such time, there are outstanding Securities of any Series which are denominated in more than one currency, then the principal amount of Securities of such Series which shall be deemed to be outstanding for the purpose of taking such action shall be determined by converting any such other currency into a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">46</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">currency that is designated upon issuance of any particular Series of Securities.  Unless otherwise specified in a Board Resolution, a supplemental indenture hereto or an Officer&#8217;s Certificate delivered pursuant to Section 2.2 of this Indenture with respect to a particular Series of Securities, such conversion shall be at the spot rate for the purchase of the designated currency as published in The Financial Times in the &#8220;Currency Rates&#8221; section (or, if The Financial Times is no longer published, or if such information is no longer available in The Financial Times, such source as may be selected in good faith by the Company) on any date of determination.  The provisions of this paragraph shall apply in determining the equivalent principal amount in respect of Securities of a Series denominated in currency other than Dollars in connection with any action taken by Holders of Securities pursuant to the terms of this Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">All decisions and determinations provided for in the preceding paragraph shall, in the absence of manifest error, to the extent permitted by law, be conclusive for all purposes and irrevocably binding upon the Trustee and all Holders.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Judgment Currency</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company agrees, to the fullest extent that it may effectively do so under applicable law, that (a) if for the purpose of obtaining judgment in any court it is necessary to convert the sum due in respect of the principal of or interest or other amount on the Securities of any Series (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Required Currency</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) into a currency in which a judgment will be rendered (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Judgment Currency</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in the City of New York the Required Currency with the Judgment Currency on the day on which final unappealable judgment is entered, unless such day is not a New York Banking Day, then the rate of exchange used shall be the rate at which in accordance with normal banking procedures the Trustee could purchase in the City of New York the Required Currency with the Judgment Currency on the New York Banking Day preceding the day on which final unappealable judgment is entered and (b) its obligations under this Indenture to make payments in the Required Currency (i) shall not be discharged or satisfied by any tender, any recovery pursuant to any judgment (whether or not entered in accordance with subsection (a)), in any currency other than the Required Currency, except to the extent that such tender or recovery shall result in the actual receipt, by the payee, of the full amount of the Required Currency expressed to be payable in respect of such payments, (ii) shall be enforceable as an alternative or additional cause of action for the purpose of recovering in the Required Currency the amount, if any, by which such actual receipt shall fall short of the full amount of the Required Currency so expressed to be payable, and (iii) shall not be affected by judgment being obtained for any other sum due under this Indenture.  For purposes of the foregoing, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">New York Banking Day</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any day except a Saturday, Sunday or a legal holiday in the City of New York on which banking institutions are authorized or required by law, regulation or executive order to close.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Force Majeure</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">47</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">or terrorism, civil or military disturbances, nuclear or natural catastrophes, pandemics, epidemics or other public health emergencies, or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer (software and hardware) services, it being understood that the Trustee shall use reasonable best efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">U.S.A. Patriot Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The parties hereto acknowledge that in accordance with Section 326 of the U.S.A. Patriot Act, the Trustee is required to obtain, verify and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee.  The parties to this Indenture agree that they will provide the Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. Patriot Act.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE XI.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">SINKING FUNDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applicability of Article</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The provisions of this Article shall be applicable to any sinking fund for the retirement of the Securities of a Series if so provided by the terms of such Securities pursuant to  Section 2.2, except as otherwise permitted or required by any form of Security of such Series issued pursuant to this Indenture.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The minimum amount of any sinking fund payment provided for by the terms of the Securities of any Series is herein referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">mandatory sinking fund payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and any other amount provided for by the terms of Securities of such Series is herein referred to as an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">optional sinking fund payment</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  If provided for by the terms of Securities of any Series, the cash amount of any sinking fund payment may be subject to reduction as provided in Section 11.2.  Each sinking fund payment shall be applied to the redemption of Securities of any Series as provided for by the terms of the Securities of such Series.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Satisfaction of Sinking Fund Payments with Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">The Company may, in satisfaction of all or any part of any sinking fund payment with respect to the Securities of any Series to be made pursuant to the terms of such Securities (1) deliver outstanding Securities of such Series to which such sinking fund payment is applicable (other than any of such Securities previously called for mandatory sinking fund redemption) and (2) apply as credit Securities of such Series to which such sinking fund payment is applicable and which have been repurchased by the Company or redeemed either at the election of the Company pursuant to the terms of such Series of Securities (except pursuant to any mandatory sinking fund) or through the application of permitted optional sinking fund payments or other optional redemptions pursuant to the terms of such Securities, provided that such Securities have not been previously so credited.  Such Securities shall be received by the Trustee, together with an Officer&#8217;s Certificate with respect thereto, not later than 15 days prior to the date on which the Trustee begins the process of selecting Securities for redemption and shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">48</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">be credited for such purpose by the Trustee at the price specified in such Securities for redemption through operation of the sinking fund and the amount of such sinking fund payment shall be reduced accordingly.  If as a result of the delivery or credit of Securities in lieu of cash payments pursuant to this Section 11.2, the principal amount of Securities of such Series to be redeemed in order to exhaust the aforesaid cash payment shall be less than $100,000, the Trustee need not call Securities of such Series for redemption, except upon receipt of a Company Order that such action be taken, and such cash payment shall be held by the Trustee or a Paying Agent and applied to the next succeeding sinking fund payment, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">, that the Trustee or such Paying Agent shall from time to time upon receipt of a Company Order pay over and deliver to the Company any cash payment so being held by the Trustee or such Paying Agent upon delivery by the Company to the Trustee of Securities of that Series purchased by the Company having an unpaid principal amount equal to the cash payment required to be released to the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Redemption of Securities for Sinking Fund</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Not less than 45 days (unless otherwise indicated in the Board Resolution, supplemental indenture hereto or Officer&#8217;s Certificate in respect of a particular Series of Securities) prior to each sinking fund payment date for any Series of Securities, the Company will deliver to the Trustee an Officer&#8217;s Certificate specifying the amount of the next ensuing mandatory sinking fund payment for that Series pursuant to the terms of that Series, the portion thereof, if any, which is to be satisfied by payment of cash and the portion thereof, if any, which is to be satisfied by delivering and crediting of Securities of that Series pursuant to Section 11.2, and the optional amount, if any, to be added in cash to the next ensuing mandatory sinking fund payment, and the Company shall thereupon be obligated to pay the amount therein specified.  Not less than 30 days (unless otherwise indicated in the Board Resolution, Officer&#8217;s Certificate or supplemental indenture in respect of a particular Series of Securities) before each such sinking fund payment date the Securities to be redeemed upon such sinking fund payment date will be selected in the manner specified in Section 3.2, and the Company shall send or cause to be sent a notice of the redemption thereof to be given in the name of and at the expense of the Company in the manner provided in and in accordance with Section 3.3.  Such notice having been duly given, the redemption of such Securities shall be made upon the terms and in the manner stated in Sections 3.4, 3.5 and 3.6.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">49</font></div></div></div><div id="icc36c5d2be824a158fed4ffa122b7147_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of the day and year first above written.</font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Precision BioSciences, Inc. </font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Its&#58;</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#91;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#93;, as Trustee</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><font><br></font></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Its&#58;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>exhibit51-sx3.htm
<DESCRIPTION>EX-5.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iaf0bf9c61d7a425ba2b34ba41f9d35d8_1"></div><div style="min-height:276.84pt;width:100%"><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 5.1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">1271 Avenue of the Americas</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">New York, New York  10020-1401</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Tel&#58; +1.212.906.1200  Fax&#58; +1.212.751.4864</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">www.lw.com</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="3" style="padding:0 1pt;vertical-align:top"><div><img alt="image_1.jpg" src="image_1.jpg" style="height:20px;margin-bottom:5pt;vertical-align:text-bottom;width:259px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">FIRM &#47; AFFILIATE OFFICES</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Austin</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Milan</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Beijing</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Munich</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Boston</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">New York</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Brussels</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Orange County</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Chicago</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Paris</font></td></tr><tr style="height:11pt"><td colspan="6" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">December 30, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Dubai</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Riyadh</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">D&#252;sseldorf</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">San Diego</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Frankfurt</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">San Francisco</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Hamburg</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Seoul</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Hong Kong</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Silicon Valley</font></td></tr><tr style="height:11pt"><td colspan="3" rowspan="4" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Precision BioSciences, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">302 East Pettigrew Street, Suite A-100</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Durham, North Carolina 27701</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Houston</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Singapore</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">London</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Tel Aviv</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Los Angeles</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Tokyo</font></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Madrid</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:157%">Washington, D.C.</font></td></tr></table></div></div><div style="margin-bottom:24pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Registration Statement on Form S-3</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">To the addressees set forth above&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We have acted as special counsel to Precision BioSciences, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in connection with its filing on the date hereof with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commission</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of a registration statement on Form S-3 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Registration Statement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), including a base prospectus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Base Prospectus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which provides that it will be supplemented by one or more prospectus supplements (each such prospectus supplement, together with the Base Prospectus, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Prospectus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Act</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), relating to the registration for issue and sale by the Company of up to $250,000,000 aggregate offering amount of (i) shares of the Company&#8217;s common stock, $0.000005 par value per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (ii) shares of one or more series of the Company&#8217;s preferred stock, $0.0001&#160;par value per share (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (iii) one or more series of the Company&#8217;s debt securities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Debt Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be issued under an indenture to be entered into between the Company, as issuer, and a trustee (a form of which is included as Exhibit 4.3 to the Registration Statement) and one or more board resolutions, supplements thereto or officer&#8217;s certificates thereunder (such indenture, together with the applicable board resolution, supplement or officer&#8217;s certificate pertaining to the applicable series of Debt Securities, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Applicable Indenture</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (iv) warrants (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Warrants</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (v) units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Units</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). The Common Stock, Preferred Stock, Debt Securities, Warrants and Units, plus any additional Common Stock, Preferred Stock, Debt Securities, Warrants and Units that may be registered pursuant to any subsequent registration statement that the Company may hereafter file with the Commission pursuant to Rule 462(b) under the Act in connection with the offering by the Company contemplated by the Registration Statement, are referred to herein collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Securities</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">We also have acted as special counsel to the Company in connection with the sale through Jefferies LLC as the sales agent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sales Agent</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) from time to time by the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt;margin-top:9pt"><font><br></font></div></div></div><div id="iaf0bf9c61d7a425ba2b34ba41f9d35d8_65"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:-2.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">December 30, 2025</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">Page 2</font></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:5.65pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">of shares of Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sale Agreement Shares</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) having an aggregate offering price of up to $60,000,000 pursuant to the Registration Statement, the Base Prospectus and the related prospectus supplement for the sale of the Sale Agreement Shares included in the Registration Statement (together with the Base Prospectus, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sale Agreement Prospectus</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and that certain Open Market Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">SM</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> dated as of June 1, 2020 between the Sales Agent and the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sale Agreement</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or related applicable Prospectus or the Sale Agreement Prospectus, other than as expressly stated herein with respect to the issuance of the Securities, including the issuance of the Sale Agreement Shares. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">As such counsel, we have examined such matters of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters. We are opining herein as to the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">DGCL</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and with respect to the opinions set forth in paragraphs 3 through 5 below, the internal laws of the State of New York, and we express no opinion with respect to the applicability thereto, or the effect thereon, of the laws of any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws of any local agencies within any state.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">When an issuance of Common Stock (other than the Sale Agreement Shares) has been duly authorized by all necessary corporate action of the Company, upon issuance, delivery and payment therefor in an amount not less than the par value thereof in the manner contemplated by the applicable Prospectus and by such corporate action, and in total amounts and numbers of shares that do not exceed the respective total amounts and numbers of shares (a) available under the certificate of incorporation, and (b) authorized by the board of directors in connection with the offering contemplated by the applicable Prospectus, such shares of Common Stock will be validly issued, fully paid and nonassessable. In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">When a series of Preferred Stock has been duly established in accordance with the terms of the Company&#8217;s certificate of incorporation and authorized by all necessary corporate action of the Company, upon issuance, delivery and payment therefor in an amount not less than the par value thereof in the manner contemplated by the applicable Prospectus and by such corporate action, and in total amounts and numbers of shares that do not exceed the respective total amounts and numbers of shares (a) available under the certificate of incorporation, and (b) authorized by the board of directors in connection with the offering contemplated by the applicable Prospectus, such shares of such series of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:-2.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">December 30, 2025</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">Page 3</font></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:5.65pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Preferred Stock will be validly issued, fully paid and nonassessable.  In rendering the foregoing opinion, we have assumed that the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the General Corporation Law of the State of Delaware.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">When the Applicable Indenture has been duly authorized, executed and delivered by all necessary corporate action of the Company, and when the specific terms of a particular series of Debt Securities have been duly established in accordance with the terms of the Applicable Indenture and authorized by all necessary corporate action of the Company, and such Debt Securities have been duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the Applicable Indenture and in the manner contemplated by the applicable Prospectus and by such corporate action, such Debt Securities will be the legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">When the applicable warrant agreement has been duly authorized, executed and delivered by all necessary corporate action of the Company, and when the specific terms of a particular issuance of Warrants have been duly established in accordance with the terms of the applicable warrant agreement and authorized by all necessary corporate action of the Company, and such Warrants have been duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the applicable warrant agreement and in the manner contemplated by the applicable Prospectus and by such corporate action (assuming the securities issuable upon exercise of such Warrants have been duly authorized and reserved for issuance by all necessary corporate action), such Warrants will be the legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">When the applicable unit agreement has been duly authorized, executed and delivered by all necessary corporate action of the Company, and when the specific terms of a particular issuance of Units have been duly authorized in accordance with the terms of the applicable unit agreement and authorized by all necessary corporate action of the Company, and such Units have been duly executed, authenticated, issued and delivered against payment therefor in accordance with the terms of the applicable unit agreement and in the manner contemplated by the applicable Prospectus and by such corporate action (assuming the securities issuable upon exercise of such Units have been duly authorized and reserved for issuance by all necessary corporate action), such Units will be the legally valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Upon the completion of all Corporate Proceedings (as defined below) relating to the Sale Agreement Shares, when the Sale Agreement Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the purchasers, and have been issued by the Company against payment therefor (not less than par value) in accordance with the Corporate Proceedings and the terms of the Sale Agreement, the issuance and sale of the Sale Agreement Shares will have been duly-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:-2.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">December 30, 2025</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">Page 4</font></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:5.65pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">authorized by all necessary corporate action of the Company, and the Sale Agreement Shares will be validly issued, fully paid and nonassessable. In rendering foregoing opinion, we have assumed that (i) the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL, (ii) upon the issuance of any of the Sale Agreement Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Company&#8217;s certificate of incorporation and (iii) certain terms of the Sale Agreement Shares to be issued by the Company from time to time will be authorized and approved by the board of directors of the Company or one or more committees thereof established by the board of directors of the Company with the authority to issue and sell Sale Agreement Shares pursuant to the Sale Agreement in accordance with the DGCL, the Company&#8217;s certificate of incorporation, the bylaws of the Company and certain resolutions of the board of directors of the Company and one or more committees thereof (with such approvals referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Corporate Proceedings</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) prior to issuance thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Our opinions are subject to&#58; (i) the effect of bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting the rights and remedies of creditors&#59; (ii) (a) the effect of general principles of equity, whether considered in a proceeding in equity or at law (including the possible unavailability of specific performance or injunctive relief), (b) concepts of materiality, reasonableness, good faith and fair dealing, and (c) the discretion of the court before which a proceeding is brought&#59; and (iii) the invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability where such indemnification or contribution is contrary to public policy.  We express no opinion as to (a) any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other economic remedies to the extent such provisions are deemed to constitute a penalty, (b) consents to, or restrictions upon, governing law, jurisdiction, venue, arbitration, remedies, or judicial relief, (c) waivers of rights or defenses, (d) any provision requiring the payment of attorneys&#8217; fees, where such payment is contrary to law or public policy, (e) any provision permitting, upon acceleration of any Debt Securities, collection of that portion of the stated principal amount thereof which might be determined to constitute unearned interest thereon, (f) the creation, validity, attachment, perfection, or priority of any lien or security interest, (g) advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary requirements, statutes of limitation, trial by jury or at law, or other procedural rights, (h) waivers of broadly or vaguely stated rights, (i) provisions for exclusivity, election or cumulation of rights or remedies, (j) provisions authorizing or validating conclusive or discretionary determinations, (k) grants of setoff rights, (l) proxies, powers and trusts, (m) provisions prohibiting, restricting, or requiring consent to assignment or transfer of any right or property, (n) any provision to the extent it requires that a claim with respect to a security denominated in other than U.S. dollars (or a judgment in respect of such a claim) be converted into U.S. dollars at a rate of exchange at a particular date, to the extent applicable law otherwise provides, and (o) the severability, if invalid, of provisions to the foregoing effect. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="padding-right:-2.63pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">December 30, 2025</font></div><div style="padding-right:-2.63pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:8.00pt">Page 5</font></div></td></tr></table></div><div style="margin-bottom:18pt;margin-top:5.65pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:11px;margin-bottom:5pt;vertical-align:text-bottom;width:172px"></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">With your consent, we have assumed (a) that each of the Debt Securities, Warrants and Units and the Applicable Indenture, warrant agreements and unit agreements governing such Securities (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Documents</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will be governed by the internal laws of the State of New York, (b) that each of the Documents has been or will be duly authorized, executed and delivered by the parties thereto, (c) that each of the Documents constitutes or will constitute legally valid and binding obligations of the parties thereto other than the Company, enforceable against each of them in accordance with their respective terms, and (d) that the status of each of the Documents as legally valid and binding obligations of the parties will not be affected by any (i) breaches of, or defaults under, agreements or instruments, (ii) violations of statutes, rules, regulations or court or governmental orders, or (iii) failures to obtain required consents, approvals or authorizations from, or to make required registrations, declarations or filings with, governmental authorities. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">This opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions of the Act. We consent to your filing this opinion as an exhibit to the Registration Statement and to the reference to our firm contained in each of the Prospectus and the Sale Agreement Prospectus under the heading &#8220;Legal Matters.&#8221; We further consent to the incorporation by reference of this letter and consent into any registration statement or post-effective amendment to the Registration Statement filed pursuant to Rule 462(b) under the Act with respect to the Securities.  In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission thereunder. </font></div><div style="margin-bottom:12pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:55.769%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely, </font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Latham &#38; Watkins LLP</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>exhibit232-sx3.htm
<DESCRIPTION>EX-23.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5245c3f294a5466aa7aeb3fa26d8e275_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.2 </font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:100%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 26, 2025, relating to the financial statements of Precision BioSciences, Inc., appearing in the Annual Report on Form 10-K of Precision BioSciences, Inc., for the year ended December 31, 2024. We also consent to the reference to us under the heading &#34;Experts&#34; in such Registration Statement.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Raleigh, North Carolina </font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">December 30, 2025</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0("(  D  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         "PU   9
M $T.  !D    1TE-4" R+C$P+C,X   R,#(U.C$R.C(Y(#$T.C,R.C4P  $
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M1T(@6%E:( ?I  P '0 4 "  )6%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
M 0    QE;E53    "    !P <P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$( %L%9@,!$0 "$0$#
M$0'_Q  ;  $! 0$! 0$!            "@@)!P8%!/_$ !0! 0
M          #_V@ , P$  A #$    >/QM\J>     )$C-Y0<=;P "/(\/  !
M[@6&@$L)B M]  (\@6&@  $L)B [?G;X   \O(T@5?&OP 3XG) V^5/
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M1A'@!7:;_ !$$"WT &?R(,'IY;:>@ $ 9O\ *_0 3(G'$V^='S\\_0._P
M   ! &;_ "OT    $^)P1-7F4"XP]P   (@@6^@  D", %_@ !$$"WT  '$$
MG!-7F4"STU^  #D 3! T>6V@&,"-(_0/SR\P^P !\><83V\ZO@ $41F N\/0
M 2!&3SS H>.[P.8!*$4/'=X &0",(U>90*/CM\  #/Y$&=?BGX  $P)R!+?#
M0!*B<L2DT[7@ $00+?0 9_(@SZ ^?.SQ2\ 0!F_ROT \_(4S1Y::?H
M   @#-_E?H    (<CT ['DX)0\=W@  "((%OH  ) C !?X  1! M]  !&D>'
ME%Q+D=SBBX  $\)PA.CYS@+/37X)\3@B=3CEB66FSP 3 G8\Y8'3\W^ ":$X
MPE7IT_/CR$,[''&$W^5^@G!.()8Z;? !.B<,2NTD2-GEEH  ,_D09U^*?@
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MPU # !G\Z_@P 9_.OX.0!Y@=7CW @#-_E?H   .8!*$:_-?@^/.6)[>7&@
MB"!;Z  "0(P 7^  $00+?0 80(\C3YM\'YYR1/L"ZP^@ ,_D09VN*3CB@39%
M#QQP!;:?'D&9K\L] .2!E H./GR7$\P*W3[  G!.()1\3@G?X[_'SY"F>WG4
M\X(EGIK\ ^?(4S^\Z?@'- \P+#3=X ,_D09U^*?@  3 G($M\. )R!.]Q0<
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M7S4  ,OGD!Z :_ !Q@)H@=?BEX^@       !_\0 *!   00!! (" P$! 0$
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M-?\ 1TV)J1*@)+2Z+F-TX%>H3%)-9TJ>;6]<Q5#,CM@HK-!QIK$P5Q$KLP'
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MJO5P%9"H%$QVU[NU< P^.C37 ,,;IP=FM"^-?JX"LA09&P[=.$U#(V(CIZN
MK(N!1/"WWA9 ,C9G'FU4A=!"5C6TM;&A_P '_\0 %!$!
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MQ1-&&"1&8L,2Z23QGVTB.N;=L] D72*ULJ=+?VM4J1J=]LH9LD71; *;$Q
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M+K7*X/Q%K]S1<WL\GA^K5S"'*X_=7Y''Y'=[/?#W>GH[H^KKQX\O7^+S.1L
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MUN@V*G5M".C8:2;QM''L!E$@OVE,K5$\ADU9JNM.CXU;E(UOXT;^IOL_8/\
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M6B+DQABOKQKM&H:L,LE7[.ODBH6,!244]NQJ-G[3%Y8:[5U8^V:?*>%>)71
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M 00BA$8AQC"$<1QC'BMNJL_%LZ>P3M*YGMA-QWJ]@;:A^RP,JY>TP(9.V<1
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M<K9C@-;#WG=!VFOAO2RRL4?-DPW44+Y &PPR BU ,&!LPJ*.;5U&4]%ZF8A
M,29\]07L'F9B$ Q!123-LS8S*5J9\\U-4N_/C,NA:F?+,>#^*J$B0^P)*Q1M
MK\HP/U3J7R -AAD!%J;?QQ;-Q('WI$N7+!1@; 13S:\/7C^92 G\79 (*6L9
MB*%<SXS$-M0%3$V@ 6W %@A&E0E1_F47!>DG]_<O:/"4W3(X_L!8+9.@)!2[
M;JC$ P8&S?J*.;5UER^Y<OW<@4*&@5]4UHM+*^M#7C'_ +_(S%WG!P'5JE_V
ME&,KTI+6#!.'1Z<:X0+!L(&2PP(+,NA;#D&$A 76K &B,C"=B\S,0@&,28\'
M\54)$A]@78$B;0C9NP*![[D"=2F=A&U&\59Z4HAK6O' :V'O*X?2DG2)#ETZ
M:(B:*IB_5-,__P")G\PM"P7R'?Q33/\ _B9_,/ S%W$' =6J6R\\HH8(%:.Q
MZN0*%#:PKZIKESY\O (PTZB,C74*28A2\4.UWE*)<N7_  /F@C+%+8F6/RR$
M6UD?8X#6P]Y2^0!L,,@(M2JT&!6]A0]H7R -AAD!%J;W:&# V544<VKJ?!W"
M%G0E1P*/5R!0H;\,5]4UST$S*2F\HK+E]RY>981;#P^7$CNH7MB09UCN."0Q
M\@:->,PQK )TD#+(ZBS^!\V$98I;Y+0H-C,5@.[R,Q=S!P'5JEH\)3=,CC^P
M%@SIH6AT*DW"BBY&)A:0Q82R*!E4H779U!':49IC=N!":[4?-C/7P]LWU0*J
M:B! 7J]^NMT"UHD7)R-H6"^0[6$[%YF8A ,44OD ;##("+4['KHMS/4]+A]*
M2=(BM(;CSS54V&N@OBVN-8!((&61U%ELZW.0(U*5-:JS+"+8>'RXD9<^?+%@
MC*?#(.@-2C4( L*HFUZ/H/+ERR)"ER,%Y9K>#;M*TE80+Y &PPR BU#ZD1$A
MFW:=4@+VUAVX2M)6$^)E:RJ8_-8E\@#889 1:G?W/[GSU4TR[,^,RI:E6RM9
M#- <R%:XD\[";*@0V=,[)8-"\1 2V6%@/"4S3*X_L!: 8,#9%11S:NO@9B[W
MH. ZM4N7+[[[[[[:P[<)6DK"2R<.CTXUP@6#1/5R!0H:A7U36,)V+S,Q" 8@
MMX-NTK25A$,&!LSJ*.;5U.(5D8#$Q*/,!P&MA[R3I@/$0%3OKH \)3-,CC^P
M%DSAT>G&N$"Q:HTJ1H_W>XZ!6J_@?-A&6*6L*6KYB'2B4?LFDYP.*_9!^.+9
MN) ^](YXI<P5N F*F&IJ($!>KWZZ1 0T+K] #8K#918).A+!>W"A6D-QYX&2
M29<;D,A9@[VA8+Y#O54V"N@OBVA?( V&&0$6H,)V+S,Q" 8DB@:;E;,83L7F
M9B$ Q1"^0!L,,@(M3!#!@;*J*.;5U\C,7<0<!U:I9+!H7B("6RPL9PZ/3C7"
M!8MI27/G\ =0EB@)>8DOD ;##("+4X?OV(@E:$Z?87R -AAD!%J:,N7+%:0W
M'G@7HL08 %EX/47X,8\T(>?TO?*E8SK'8(C^3MM!"C;"H2+287L O:*)HA$;
MB[G]SY\]1!6+)=' 9(=GWS+RJL+-O/N=7"$K?L$/J*PQU.@" ME00^1F+O=@
MX#JU2Y<ON6CPE-TR./[ 7)F6$6@\/EQ(R,*+FS;+JY"&.IT 2%LJ#)?(U,(2
M$,)9%!0--RMFT01);8PBH$F@7R -AAD!%J$X='IQKA L&B>!F+N(. ZM4M'A
M*9IE<?V M#B%9& Q,2CS *K@&@AA%51*+W-%C0'@<H]% @!0 FU7KV>J5<8P
M*.2JO/4J)CDPHO4)[QYA]O@&9\H<!K8>\B@:;E;,,KLX2B82HMB*7R -AAD!
M%J+"=B\S,0@&*(/"4W3*X_L!8!DDF7&Y#(64[K"=B\S,0@&**7R -AAD!%J)
MD$F7&Q#(68N[#'4Z ("V5!"8U@$@@99'46<R\JJ+-O/N=0/"4S3(X_L!=-+G
MS_TANV$JWJPH>V1 /Y6"<&BF7+ESW'@_JJA(D/L"*=#F/S4HA^M#1D9MT*\(
M!N1]BM1:.N>I0?:9OZ)$R,SL&F0#_P"PAQJCH+MKXD%?"-"([)G<_N?/_B*6
M'NM:"V/ 1C#+<1D-A]$;?8Z[NPOD ;##("+4*((DML854"31EHTKQ$!+986$
MZ8#Q$!4[ZZ /"4S3(X_L!=U+E]]]]]]M8=N$K25A);.'1Z<:X0+%L)*Q1\T3
M#=1?9G0FR0([P:>SI@/&<!4[ZZ#>#;M*TE808A.1L,3$H\P88ZG0! 6RH)?%
M6>E*(:UKT>$INF1Q_8"P\#,7<P<!U:I8H&FY6S>(5D8#$Q+H\P?@O,!&6*6L
MBTJM(/&K/C3@ 90SEH/:0<.E8:V4W!QR=(/AC4]QHH&FY6S' :V'O/BK/2E$
M-:U^JIL-=!?%M7#Z4DZ1W0+6B1<G([H.T5\-Z645I#<>>,Z8#Q4!4[ZZ"7R
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MX;N2VD5A?__:  P# 0 "  ,    0D      D   DDD  D       D    D@
M $@      @  @  $   D  DDDD  $@$@@    DD  D   @
M$    $@$@     D   @$       $$      @     @   @$ $D@DD $$ @
M$@ $ D    $                 @@   D      $@   $    @$       @
M  @@ @ $    @   $$   @@@@  D  @ @   $$               $@    $
M@      D   $@        @  $   $$ $           @@  $$ @  $@ $$
M   @@   $ $ @D       @    D      $@  @ $   D@ $@$  @   @  @
M    @ $  $$   @@    D  @      @    @ @$@@     @@    $@
M$    $   $$$  @  $@$ $ $        @   @@  $$$   $@ $$$$   $
M $ $ D      $ $    D      $@  D @@    $  $ $@$@  $@ $   $$$$
M  $$   @     D  @@@D      @ @ @$$     $ D@@  $@      D   DD
M  @@@$@   @ @      @   $DD   @@  $$@   $@ $$  $    $   D DD
M     @  @   D      $@ $  $$   $   @  @@@ $    $  @     $$
M@@@@  D  @@$$@    @  D@D@  DD@    $$  $@      D  @   @ @@
M $      @    @ $$  $  @@  $$  @ $@ $$     $$$$          @$$
M  @  D      $@     @@$   @ @        @    $   $  $$   @@$$  D
M  @@ D   @ D          $ @                $$  $$ @ $$ $$
M $$   @ @@  @@  @  $   $     $  @  $ @        __Q  4$0$
M              "P_]H " $# 0$_$ '/_\0 %!$!
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MSE9_L;?X-:L.!5\X:>S?3$B<ED.!5\X:2P9_!?# )OM=C?%(9?.\+B'91,0
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%K_\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
M_]C_X  02D9)1@ ! 0( Q #$  #_X0"N17AI9@  24DJ  @    ' !(! P !
M     0   !H!!0 !    8@   !L!!0 !    :@   "@! P !     P   #$!
M @ -    <@   #(! @ 4    @    &F'!  !    E         !A#P  %
M &$/   4    1TE-4" R+C$P+C,X   R,#(U.C$R.C(Y(#$T.C(X.C(P  $
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M1T(@6%E:( ?I  P '0 4 !L .F%C<W!-4T94
M          #VU@ !     -,M;&-M<P
M                                #61E<V,   $@    0&-P<G0   %@
M    -G=T<'0   &8    %&-H860   &L    +')865H   '8    %&)865H
M  'L    %&=865H   (     %')44D,   (4    (&=44D,   (4    (&)4
M4D,   (4    (&-H<FT   (T    )&1M;F0   )8    )&1M9&0   )\
M)&UL=6,          0    QE;E53    )    !P 1P!) $T 4  @ &( =0!I
M &P =  M &D ;@ @ ', 4@!' $)M;'5C          $    ,96Y54P   !H
M   < %  =0!B &P :0!C "  1 !O &T 80!I &X  %A96B        #VU@ !
M     -,M<V8S,@       0Q"   %WO__\R4   >3  #]D/__^Z'___VB   #
MW   P&Y865H@        ;Z   #CU   #D%A96B         DGP  #X0  +;$
M6%E:(        &*7  "WAP  &-EP87)A       #     F9F  #RIP  #5D
M !/0   *6V-H<FT       ,     H]<  %1\  !,S0  F9H  "9G   /7&UL
M=6,          0    QE;E53    "    !P 1P!) $T 4&UL=6,
M 0    QE;E53    "    !P <P!2 $< 0O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_" !$( &0$X@,!$0 "$0$#
M$0'_Q  >  $! 0$! 0 # 0$         "@D(!P8#! 4! O_$ !0! 0
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M2\ 'RYQR=N']( $2I^<MC!R^11G]DTW*K 9ADGY6R:1@'^$1!Y\>>%9YI:
M"( Z!*_@ #BDC9*6C:(P1)\2C@W$ !/:8*ETQZL 87$Z@.S2RH_*?B()#8LI
M5 )NS$<L<.X        " ,I<-H    <I$6!O@8(FTI2J  #%LFG++3L\ 'R)
M!B;8E)8 )!#QXM<  ,;R9,WG,&"HXUN  .$2/$Z0/$2[H^@!$T?U3E,I0-K
M 2PG3QYD4F@ EJ,G2[$]&,<29T[N.;"Y0_TGN,%BZX], .6"*HWM,$C:4I7
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M$K_  .)B-PI7/6R4TU7*I#_0 3TF#)=&>L@&%I.J7%GN)D&2_FF9Q0:DE*X
M !AV3CE5QJ<"7PYN/6BC8E /JC9\Y\-S3[ $ 92X;0   _3(9ST [-!_AX6<
M'E/YKZ #%\FC+*3M, 'QA!L;9E)( ) SQLM@ .8B* [J.@0?J'(IRT6U'2(/
MQD%1K(4ZGB)#F>EGG1<\>K$\Y@V6G'5P/^3*XX4.V36(Y&.O #( F"/;SI4K
MX!BJ36GMYZT69@'X"& ^^.V3\9_./&C@PI^-?@ 1 '0A7V  <3D;92T;0DDA
MF^55FJ( )Z3!DNF/5@#"XG4+BSW$_F$3IX ?0FOA2N   88DZ)7Z=_@
M$ 9KF=Y 'KIIT#A\CC*9S94 \.(=C5,JG !BV33EE!VH #XL@W-M"D@ $@9X
MR6Q &'!.46E'60!E 2Q%'AN #R(A@-[R@T$5IRJ=>%H ,:"9HK0-+     #E
M8BL!O*4+@X\(Q@;2%+ !Q 1Q%,1LT >'D/!J.58  B!.@2OT  XG(VRE8VF.
M:R+L^]+5CT4 GD,'BZ(]: ,*B=@N+/<08UDRX-HRED X-/!CI,YM)PC]LM_/
M[H     ! &  =S%BP)]3 \N />@ 1:'@Q=<?U@#%\FC+*SM$ 'QI!J;:%)
M)!3QLM> )#3FPN!/R 'G)"P=]%>8.)R-LI6-I@3<&)1N648@S=))2DPVP
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MRH6 GZ.3I/G4)_JZ^+3UJF.GKBMTL&;)KYI=K+&H] OTLYGODQ9@)2CF9*K
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M^3]G:;ED$*UICRXK5HYTM-\&:2S<8J9F.: 6>!)H=)H;1^O_ /_$ !01 0
M                 *#_V@ ( 0,! 3\!?S__Q  4$0$
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MC+:KI06V*>CKX'Z<T#BOHPW2;#8>6(O"O;YR8[?,2']T+D'Q?JQ- H'F#?#
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MD5/%D=211X,U5+Q.R/G IKK>*MYR._F_0]JNT ';]:=6[CR_/#M30<=O>@)
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MRQ%T3VS6M0TIEDV A!E0A25?=L)@?4/%MHI93)5<6KZZP2[%V80(RU]!W?\
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M:RHFRKZE3VZ<0 C7FEECCZ=*+O+<:%!J%6AO"K=*6- J( D,=6( H4:]+ +
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M]:AZDJ(W2J/'*::"+I4-WFBY%0@+JACO">L56@V;RQW,5\(^G[KLBK@>./\
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M61D4]+1N^CSF*:LJ*F/J4Y6E+]=8X842**)%CBCC4)''&@"HB(N%5$4!54
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MJ[O2(Y?J;1VVJ>W(R.&<&(I2 PX..EH %'E%AE>/?V?;;]6H=BO2?V7/2"3
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MKA'F'Q*ZJBIER55V !DR2J.0/DK'MXIZ2 :PTL$5/"O;RQ01K'&.P [*H'8
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M1%;JJ-WF^&8CXL<4L;Q2QV>V))%+&L4D;I10J\<D235"1NC JT:SSJC J)I
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M>]&+X;[\VKQ<-*S)FW]H^WU9Y%)7)\ QT@]$@C-47/1B;H!QOE"8#3D-2B1
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M8386)T79[UF[.LQ!%?Y$; B&(H#\ON7=-9IIL2QO*7W0E&U8JRA17%A")?\
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MW@"M:BL71N- #KQ>OI2TIJ''))XJ/U+,%A[*+??@GP$D[.<9ZL@%ZY4^M_\
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M$O83WV(1-E;!KM'9,W32M$&X8K@P32\+"%GA; F(8BTKZ,J/@#Z(#8/0@
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M -.QZ]+\Z?D?T>('KN=AD0'#4%N^ZGH. F(+TC5]EB'L\2\"266+Q!M)^0
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M()_:_O'T.?"A!0(=D%!R7[Z-<3!X^J6@,W]A+_0_K$]O\V?2]00$G@EZUN!
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M(  !(    !!  (     !  )()  (( !    !   )  (         (    ((
M  ((( !  !   ((  !(  (!     ((  (!!  (    !   !!)( ((  ! !
M!!)       !     ((       (     ( (  (! ! ( !(  !    ((   (
M!(   ((   !     )  !         (          (        !!    !) )!
M  (  !! !(              (!  (( )(()  ((    ! )!!     !   !
M  (     ! (   ( (   !!  ( !      )!  !(   !   !  !!!)  !!(
M !  !((   !(     (  !(()    !    !!!( !!( !! ! !( !( (  (  !
M!!    (   !!( (   !     !   !!!   !    !))( ! !   !   !( (((
M )((((  !(!    (  ((   !!  !  )  ) ( (   (((    (((  (   !
M   (( (  (! (! ! (( (    ( ( ((  !   !)   (   !(     ((! ! (
M !   !!!)( !   (   ( (((   (! !!! !)( ! !  (   !(  !(   )
M      !!   !   ))(  (   ) (!  (  !   (  ! ()    !   !((( (!
M ! !)(!!      !)!   (   ((    (       !)) (     !   ((
M (( !   !        (    (      (   (() !      !    )
M!!  !      !  ! !)  )    !         !  ! !)   ( )   !  ( (( (
M   ( ( !       (      !( !   ((    (   ( )    )      !
M   !  (  )  ( !)  !  ( !()       !__Q  4$0$
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M$/;*!>CD#K,.=,F)0&@]-;/ @W3;<\(VY'%6=G&<@T?O2(J*O_\ B?=^5%%
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M!,M5]Y-<Y<X2U'<E,Z$\13](1S?G1G@D=PQTBDTS!GXB%!!DKMC\F"E+W$X
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M3F.@6S*.1I .5HZ@[5,.*( < IVE?(V)GHFL/D@I+.NHD;WV6<O9 D_ Q0
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MEF2ASFD1&:1E%H,R2],8"/T6DD$1;85<$2$!,(CHSS#U50X%+"32&"0A!Z9
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*='(!>/\ @=/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>precisionlogoa.jpg
<TEXT>
begin 644 precisionlogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !0 3 # 2(  A$! Q$!_\0
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MJ>K6.BVWVC4+VWL+?<%\VYE6-<GH,L0,U.X%NBN?_P"%A>%O^AET?_P/B_\
MBJEM/&_AR_N8[>VU_2[BXD8*D45Y&SN?0 -DFJY)=A71MT454U35[#0[-[O4
MKVWT^T3[T]U*L2+]68@5.XRW17.Z+\1O"?B2[%KI'BC1M4NCT@LM0BF<_P#
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M;^!_^P]_[1>OL;6-6M- TF]U/4)UM;"R@>YN)W^['&BEF8^P )KXY_X*A?\
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MJ8X:I*DE[1^[)NS[.[T]'T^[L2_M]_\ ([? 7_L9A_Z-MJ^L?"__ "+.D?\
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MXZAU[1V-Q9RXBU#3)'(BO(<_=/HPY*MV/J"0?URT+PAX*^)C^'_BE!X6LO\
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M8*L#P00<$&OE#Q/^P@^@>)+OQ#\'_'NJ?#6]N3NET^$M):.<YVC:P*KWVMO
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MTA]:TCXL6=QXM6R:[U6Q>PTV72F;R$"'S9$=7&[<<9#9(^7&*]+U/_D&W?\
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M_P !KHJ* "N#U[P9XB;QQ/XAT'5M/LVGL8[*2*]M'FX1V;(VNO\ >_2N\HH
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.,<D(BA5R?H!5NB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Dec. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001357874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">PRECISION BIOSCIENCES INC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">S-3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings<br></strong></div></th>
<th class="th">
<div>Dec. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=1', window );">Offering: 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Common Stock, $0.000005 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=2', window );">Offering: 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Preferred Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=3', window );">Offering: 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Debt<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Debt Securities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=4', window );">Offering: 4</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Depositary Shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=5', window );">Offering: 5</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Warrants<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=6', window );">Offering: 6</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Other<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Units<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingAxis=7', window );">Offering: 7</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457oFlg', window );">Rule 457(o)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Unallocated (Universal) Shelf<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 250,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 34,525.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">1. An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities.

2. Includes rights to acquire common stock or preferred stock of the Company under any shareholder rights plan then in effect, if applicable under the terms of any such plan.

3. Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities, depositary shares or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $250,000,000.

4. The proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

5. The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended.

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457oFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457oFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=5">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=5</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=6">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=6</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=7">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=7</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Dec. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 250,000,000.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlPrevslyPdAmt', window );">Previously Paid Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">34,525.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 34,525.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlPrevslyPdAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlPrevslyPdAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>8</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="dtilexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dtilexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dtilexfilingfees.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="dtilexfilingfees.htm">dtilexfilingfees.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="43">http://xbrl.sec.gov/ffd/2025q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "dtilexfilingfees.htm": {
   "dts": {
    "inline": {
     "local": [
      "dtilexfilingfees.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025q4/ffd-2025q4.xsd"
     ]
    }
   },
   "keyStandard": 21,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 14,
    "http://xbrl.sec.gov/ffd/2025q4": 12,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 8,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025q4": 43,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dtilexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "offrl_1",
      "name": "ffd:Rule457oFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dtilexfilingfees.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dtilexfilingfees.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "rc",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "dtilexfilingfees.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal8ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025q4",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001628280-25-059077-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-059077-xbrl.zip
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MQ$:#P4I7J! $.B8J7NQ..&+ F$*L#BKP9]G_69D*HQ34E3,7Y"&8Y9JT5$T
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MB0\#P@=YC\R0DRXY.WM[3D:@N?)(LY@YZY(^9YIY3/Y%S0<JF:X=$Z'9HBQ
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M0//S?>)%W4^K(/"]X770  @3PH,+RR ]%UH :0:?E%1]V3.8H(8R*B8Y@2%
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M"75@ZZ(ZD9;9^S]02P$"% ,4    " "80)Y;.) DB"0/  "=E   %
M        @ $     9'1I;&5X9FEL:6YG9F5E<RYH=&U02P4&      $  0!"
)    5@\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>dtilexfilingfees_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025q4/ffd-2025q4.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="offrl_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>3</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="offrl_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>4</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="offrl_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>5</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="offrl_6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>6</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <context id="offrl_7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001357874</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>7</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-30</startDate>
            <endDate>2025-12-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-426">S-3</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-427">S-3</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-428">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-429">0001357874</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-430">PRECISION BIOSCIENCES INC</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="7"
      id="ixv-434"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_2"
      decimals="7"
      id="ixv-435"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_3"
      decimals="7"
      id="ixv-436"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_4"
      decimals="7"
      id="ixv-437"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_5"
      decimals="7"
      id="ixv-438"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeRate
      contextRef="offrl_6"
      decimals="7"
      id="ixv-439"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FormTp contextRef="rc" id="ixv-518">S-3</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-519">PRECISION BIOSCIENCES INC</dei:EntityRegistrantName>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-520">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-521">Common Stock, $0.000005 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_1" id="ixv-522">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-523">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-524">Preferred Stock, $0.0001 par value per share</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_2" id="ixv-525">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_3" id="ixv-526">Debt</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_3" id="ixv-527">Debt Securities</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_3" id="ixv-528">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_4" id="ixv-529">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_4" id="ixv-530">Depositary Shares</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_4" id="ixv-531">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_5" id="ixv-532">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_5" id="ixv-533">Warrants</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_5" id="ixv-534">true</ffd:Rule457oFlg>
    <ffd:OfferingSctyTp contextRef="offrl_6" id="ixv-535">Other</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_6" id="ixv-536">Units</ffd:OfferingSctyTitl>
    <ffd:Rule457oFlg contextRef="offrl_6" id="ixv-537">true</ffd:Rule457oFlg>
    <ffd:PrevslyPdFlg contextRef="offrl_7" id="ixv-538">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_7" id="ixv-539">Unallocated (Universal) Shelf</ffd:OfferingSctyTp>
    <ffd:Rule457oFlg contextRef="offrl_7" id="ixv-540">true</ffd:Rule457oFlg>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_7"
      decimals="2"
      id="ixv-541"
      unitRef="USD">250000000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_7"
      decimals="7"
      id="ixv-542"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_7"
      decimals="2"
      id="ixv-543"
      unitRef="USD">34525.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-544" unitRef="USD">250000000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-545" unitRef="USD">34525.00</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="2" id="ixv-546" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-547" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-548" unitRef="USD">34525.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_7" id="ixv-549">1. An unspecified number of securities or aggregate principal amount, as applicable, is being registered as may from time to time be offered at unspecified prices and, in addition, an unspecified number of additional shares of common stock is being registered as may be issued from time to time upon conversion of any debt securities that are convertible into common stock or pursuant to any anti-dilution adjustments with respect to any such convertible debt securities.

2. Includes rights to acquire common stock or preferred stock of the Company under any shareholder rights plan then in effect, if applicable under the terms of any such plan.

3. Estimated solely for the purpose of calculating the registration fee. No separate consideration will be received for shares of common stock that are issued upon conversion of debt securities, depositary shares or preferred stock or upon exercise of common stock warrants registered hereunder. The aggregate maximum offering price of all securities issued pursuant to this registration statement will not exceed $250,000,000.

4. The proposed maximum aggregate offering price per class of security will be determined from time to time by the registrant in connection with the issuance by the registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act.

5. The registration fee has been calculated in accordance with Rule 457(o) under the Securities Act of 1933, as amended.

</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
